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Gene therapy is a promising application for the treatment of patients with inherited or 
acquired diseases. It can be performed either in vivo or ex vivo and the principle 
concept involved is the introduction of exogenous genetic material into a patient. In 
ex vivo gene therapy, therapeutic genes are delivered into transplantable cells where 
they must maintain persistent expression as failure to do so would result in a loss of 
therapeutic benefits. Transgene integration within the host genome is the most 
common way to induce persistent expression, however, most if not all approaches 
taken to achieve this feat are plagued by technical issues and safety concerns, 
namely insertional mutagenesis and transgene silencing. Hence, it is imperative to 
find an approach that induces persistent transgene expression without compromising 
genomic stability. Furthermore, it is necessary to identify genomic sites that are 
resistant to epigenetic silencing phenomena and upon disruption would not be 
detrimental to the host cell. The adeno-associated integration site-1 locus (AAVS1) 
on human chromosome 19 is one such site and is therefore regarded as a safe 
harbour for the integration of therapeutic genes.  
This study focuses on targeting the AAVS1 in human embryonic stem cells (hESCs) 
and HeLa cells via a novel approach. First, through conventional homologous 
recombination a floxed neomycin resistance marker was introduced into this locus. It 
was then replaced (exchanged) with a gene of interest (EGFP or HSVtk) using two 
baculoviral vectors; one expressing Cre recombinase and the other the transgene 
donor. Through this baculoviral vector-mediated Cre recombinase-mediated cassette 
exchange (BV-RMCE) technique significantly high transgene integration efficiencies 
were achieved at the AAVS1, allowing for the generation of transgenic hESCs and 
HeLa cells.   
ix 
 
To ensure that the AAVS1-integrated transgene was resistant to epigenetic silencing 
phenomena, EGFP-hESCs and EGFP-HeLa cells generated through BV-RMCE were 
expanded for 20 and 24 passages respectively in the absence of drug selection. 
While both these transgenic cell lines (underwent site-specific integration) displayed 
no evidence of silencing, hESC lines that underwent random integration displayed a 
clear loss of EGFP expression within 7 passages.  
Following genetic modification, EGFP-hESCs continued to express stem cell markers 
but failed to express lineage markers; revealing that the two-step genetic modification 
process incorporated in BV-RMCE impacted neither the phenotype nor the 
pluripotency of these cells. EGFP-hESCs were differentiated into neural stem cells, 
mesenchymal stem cells and dendritic cells. The ability to differentiate into 
ectodermal and mesodermal lineages further demonstrated that the differential 
potential of these transgenic cells remained intact. Like EGFP-hESCs, the 
differentiated progenies too displayed no loss of transgene expression upon 
expansion. These results confirmed that transgene integration within the AAVS1 did 
not lead to genomic instability and that transcriptional competence was still 
maintained across diverse cell types following hESC differentiation.   
The study was concluded by demonstrating the clinical potential of BV-RMCE. The 
HSVtk suicide gene was integrated within the AAVS1 and the result was TK 
expressing neural stem cells with the capability of killing U87 glioma cells with high 
efficacy in the presence of GCV. These cells also displayed tumor tropism; 
confirming that they were functionally adequate for glioma therapy. The results 
obtained throughout the entire study and the use of this technology in the field of 
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1. An Introduction to Gene Therapy 
1.1 Genetic Modification Procedures  
In today’s world of scientific advancement, gene therapy is being looked upon more 
favourably with regard to its application in the treatment of individuals with inherited 
or acquired diseases. In vivo gene therapy is defined as the introduction of 
exogenous genetic material into a patient and ex vivo therapy is defined as the 
transplantation of genetically modified autologous or allogenic cells or tissues. 
The principle concept surrounding gene therapy is the introduction of genetic 
modifications either in vivo or ex vivo which include (i) gene augmentation – the 
addition of genes, (ii) gene knockdown – the silencing of genes and (iii) gene editing 
– the alteration of genes.  
   
1.1.1 Gene Augmentation 
This is the most common form of genetic modification and is utilised in therapeutic 
applications for the treatment of individuals with metabolic deficiencies or cancers 
resulting from a defective gene. Gene augmentation aims at introducing a healthy 
gene (a transgene) into a patient thus facilitating the expression of a protein which 
was otherwise lacking. The process does not replace the defective gene and is 
hence referred to as gene augmentation since multiple copies of the gene, both 
defective and healthy exist in the patient.  
Studies have revealed that a defect in the p53 tumor suppressor gene is responsible 
for many human cancers [1]. Therefore, by intraperitoneal infusion of an adenoviral 
vector expressing a wild-type p53 gene, improved survival times were achieved in 
patients with advanced ovarian cancer [2, 3]. Furthermore, it has been revealed that 
a defect in the IL2RG gene hinders the proliferation and differentiation of 
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hematopoietic progenitor cells (HPCs) and is thus responsible for a severely 
compromised immune system [4]. Therefore, by transplanting autologous HPCs that 
were modified with a retroviral vector expressing a wild-type IL2RG gene, patients 
with SCID-X1 were successfully able to produce functional T-cells and natural killer 
(NK) cells [5]. Both these examples highlight how gene augmentation has been 
successfully utilised in both in vivo and ex vivo gene therapy. 
  
1.1.2 Gene Knockdown 
Gene knockdown is considered the opposite of gene augmentation as it aims to 
reduce or completely silence the expression of a gene. This is achieved by utilising 
RNA interference (RNAi). RNAi is a naturally occurring post-transcriptional gene 
regulatory process that uses small non-coding RNA molecules, namely short 
interfering RNAs (siRNAs) and micro RNAs (miRNAs). siRNAs and miRNAs defer 
from one another in that the former molecule’s sequence is directly complementary to 
that of its target mRNA and thus induces silencing via a cleavage-dependent 
pathway. miRNAs however contain mismatches in their sequences and thus target a 
range of mRNAs where they induce silencing by either a cleavage or translational 
repression mechanism [6]. Short hairpin RNAs (shRNAs), a type of RNA molecule 
that mimics the mechanism of miRNAs can also induce post-transcriptional silencing.  
Studies have revealed that miR-26a consists of anti-proliferation and apoptotic 
properties and is thus down-regulated in certain tumors [7]. Therefore, by systemic 
administration of an adeno-associated viral (AAV) vector expressing miR-26a, tumor 
suppression was achieved in a mouse liver cancer model [8]. Furthermore, it has 
been revealed that the CCR5 gene which encodes for a cell-surface receptor is 
responsible for HIV infection and replication [9, 10]. Therefore, by transplanting 
autologous HPCs that were modified with a lentiviral vector expressing small non-
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coding RNAs directed against the CCR5 gene, it was found that these cells conferred 
a selective advantage which led to the suppression of HIV in patients with AIDS-
related lymphoma [11]. These examples highlight the therapeutic potential of RNAi 
molecules. 
   
1.1.3 Gene Editing 
When compared with gene augmentation and gene knockdown, gene editing is a 
completely different form of genetic modification. Rather than use a transgene to 
enhance gene expression or a RNAi molecule to silence gene expression, this 
process aims at altering the gene itself by utilising the cell’s very own homologous 
recombination mechanism.  
Studies have revealed that a mutation in the HPRT1 gene results in Lesch-Nyhan 
disease [12]. By utilising conventional homologous recombination, this mutation was 
successfully corrected in mouse HPCs [13].Furthermore,  as discussed previously, a 
mutation in the IL2RG gene results in SCID-X1. By using zinc-finger nucleases 
(ZFNs) this mutation too was successfully corrected in human T-cells via a 
homology-directed repair mechanism [14].  
As discussed previously the CCR5 gene is responsible for HIV infection and 
replication. Therefore, by using ZFNs directed against the CCR5 gene in human T-
cells and HPCs, HIV suppression was achieved in a humanized mouse model [15, 
16]. The disruption of the gene was attributed to a non-homologous end-joining 
mechanism. These examples highlight as to how gene editing can be utilised in 
therapeutic applications either by the correction of mutations found in defective 





1.2 Viral Vectors and Transgene Delivery Systems 
Having focussed on the various forms of genetic modification we turn our attention as 
to how these modifications are made possible. For gene augmentation, gene 
knockdown and gene editing to be successful, a transgene (therapeutic gene or 
RNAi molecule) must be introduced into a patient via the use of viral vectors or non-
viral delivery systems. This section focuses on the various types of gene delivery 
systems and provides examples of their therapeutic potential and clinical success.         
 
1.2.1 Non-Viral Gene Delivery 
This approach utilises either physical or chemical systems to deliver a gene 
expressing plasmid into a patient. There are several advantages associated with 
plasmids, the most important being their lack of viral components. Furthermore, the 
lack of a size constraint which enables these systems to deliver unlimited amounts of 
DNA together with their inability to stimulate any pre-existing antigen-dependent 
immunity supports their use in therapeutic applications. By being able to successfully 
deliver genes in vitro, non-viral systems have demonstrated their ex vivo gene 
therapy potential [17].  
However, one major drawback associated with these systems is their inability to 
efficiently deliver genes in vivo. Furthermore, when considering their use in ex vivo 
gene therapy, once delivered into a cell, plasmids exist episomally and thus provide 
transient transgene expression which would lead to the loss of therapeutic benefits 
over time. But, when compared with their viral counterparts, plasmids are considered 
as a safer alternative and hence efforts are being made to enhance the efficacy of 




1.2.1.1 Physical Non-Viral Gene Delivery 
In this approach a physical force is utilised to temporarily disrupt the cell membrane 
and thus facilitates gene uptake. Physical forces currently being studied include DNA 
injection, hydrodynamic gene transfer, biolistic particle delivery, electroporation, and 
sonoporation. 
DNA injection is the simplest physical non-viral approach that aims at delivering a 
gene directly into a patient’s tissues. It has been utilised in the treatment of patients 
with chronic myocardial ischemia [18]. Although considered a safe approach, DNA 
injection can lead to localised pain, oedema or bleeding at the site of injection.  
Hydrodynamic gene transfer is similar to DNA injection but defers from the fact that 
it involves the injection of large amounts of DNA within a short period of time. It has 
the potential to be utilised for the delivery of genes into the liver [19]. However, the 
requirement for large injection volumes that is beyond the acceptable level of a 
patient make hydrodynamic gene transfer a risky option.  
Biolistic particle delivery utilises a gene gun that enables tissue bombardment with 
DNA-coated heavy metal particles. Tungsten, gold and silver are some of the metals 
used in this approach. The efficiency of gene delivery and tissue penetration as well 
as the degree of tissue injury is determined by multiple parameters such as gas 
pressure, the size of the particle and the dosing frequency. Biolistic particle delivery 
has the potential to be utilised in the treatment of diabetes [20]. The cytotoxic effects 
caused by tungsten and the expenses that surround gold and silver are some of the 
disadvantages associated with this approach.       
Electroporation utilises an electric field to alter cell membrane permeability, and 
thus facilitates gene uptake. In this approach, the tissue is first injected with a 
plasmid followed by exposure to electric pulses. Electroporation has the potential to 
be utilised in localised gene therapy where it is necessary to deliver genes into a 
6 
 
specific location within a certain tissue and also in the treatment of diabetes [21, 22]. 
However, the limited accessibility of the electrodes to the internal organs hinders its 
use in therapeutic applications.              
Sonoporation utilises ultrasound waves together with a contrast agent or micro-
bubble to alter the structure of a cell membrane, and thus facilitates gene uptake. It 
has the potential to be utilised for the delivery of genes into the heart and also in the 
treatment of bone deformities (osteogenesis) [23, 24]. Unlike electroporation, 
sonoporation can reach the internal organs; however, the use of plasmid DNA leads 
to transient gene expression which is futile in applications where long-term 
therapeutic benefits are required.  
  
1.2.1.2 Chemical Non-Viral Gene Delivery 
This approach uses a chemical compound that can form complexes with naked DNA 
molecules by electrostatic interactions. These complexes protect the DNA molecule 
and facilitate its cellular uptake. Chemical compound currently being studied include 
cationic lipids, cationic polymers and inorganic nano-particles. 
Cationic lipids also referred to as liposomes contain a positively charged hydrophilic 
head and hydrophobic tail which are connected by a linker structure. Owing to its 
positive charge, the hydrophilic head can bind to negatively charged DNA molecules 
and protect them against nucleases. This liposome-DNA complex is referred to as a 
lipoplex. Cationic lipids also facilitate the cellular uptake of DNA molecules by 
interacting with the negatively charged cell membrane. The efficiency of gene 
delivery as well as the degree of cytotoxicity and immunogenicity is determined by 
multiple parameters such as the molecular structure, the charge ratio and the co-lipid 
properties. These compounds have the potential to be utilised in the treatment of 
prostate cancer and influenza A infection [25, 26]. Furthermore, they are inexpensive 
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to produce and can be engineered for target specificity. The formation of aggregates 
with serum components is the major disadvantage associated with cationic lipids.  
Cationic polymers consist typically of amine groups that remain non-protonated 
under physiological pH conditions. Like cationic lipids, they too can bind to DNA 
molecules and the resulting complex is referred to as a polyplex. Once a polyplex is 
engulfed by an endosome, the non-protonated amine groups act as a proton sponge 
and neutralise protons that are actively pumped into the endosome. This causes the 
endosome to swell and rupture. By preventing acidification of the endosomal pH, 
cationic polymers prevent the endosomal-lysosomal pathway, thus protecting the 
DNA molecules from degradation. The efficiency of gene delivery as well as the 
degree of cytotoxicity and immunogenicity is determined by multiple parameters such 
as the molecular weight, the configuration and the charge ratio. These compounds 
have been used in the treatment of patients with cystic fibrosis [27]. Furthermore, 
they have the potential to be utilised in the treatment of osteosarcoma lung 
metastases [28]. Although considered less cytotoxic and immunogenic than 
lipoplexes, cationic polymers too form aggregates with serum thus hindering their use 
in therapeutic applications.  
Inorganic nano-particles are prepared typically from metals or inorganic salts and 
can therefore be coated with other substances to facilitate gene uptake. Like cationic 
lipids and polymers, nano-particles can also bind to DNA molecules. These 
compounds have the potential to be utilised for the delivery of genes into the 
respiratory tract and ocular cells [29, 30]. Furthermore, their small size enables them 
to bypass physical and chemical barriers as well as be transported directly into the 
nucleus. With regard to other chemical compounds, nano-particles induce the least 
amount of cytotoxicity and lack immunogenic properties. However, as plasmid DNA 
is used, these compounds provide transient gene expression, similar to all other non-
viral gene delivery approaches.      
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1.2.2 Viral Gene Delivery 
This approach uses a vector which is derived from an animal virus to deliver a gene 
into a patient. There are several advantages associated with these vectors, the most 
important being, (with the exception of some) their ability to efficiently deliver genes 
across a range of cell types. Viral-vectors are thus highly regarded as suitable 
candidates for their use in ex vivo gene therapy. Furthermore, by integrating into a 
host chromosome, certain viral vectors induce persistent gene expression unlike their 
plasmid counterparts.  
A few major drawbacks however are associated with these vectors, the most 
important being safety concerns regarding their pathogenicity. Furthermore, their 
limited DNA carrying capacity owing to size constraints together with their highly 
immunogenic properties hinders their use in therapeutic applications. 
Retroviral vectors were the first viral vectors to be used in human ex vivo gene 
therapy trials [5]. Being derived from mouse Moloney retroviruses these vectors can 
be pseudotyped, thereby enabling their entry into non-mouse cells. Transplantable 
cells modified by retroviral vectors have been used in the treatment of patients with 
immune diseases such as X-CGD and WAS as well as cancers such as melanoma 
and neuroblastoma [31-34]. These vectors provide persistent gene expression by 
integrating within the host genome. However, whilst integration is ideal for achieving 
long-term therapeutic benefits, the random nature of it can lead to insertional 
mutagenesis. Furthermore, their inability to transduce non-dividing cells and their low 
viral titres has led to a shift in attention towards lentiviral vectors. 
Lentiviral vectors derived from the retroviridae family can be propagated in high 
viral titres. They also have the ability to transduce both dividing and non-dividing 
cells, thus supporting their use in ex vivo gene therapy. Transplantable cells modified 
by lentiviral vectors have been used in the treatment of patients with β-thalassaemia-
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based anaemia, ALD and AIDS-related lymphoma [11, 35, 36]. Since lentiviral 
vectors are derived from human viruses such as HIV, numerous safety concerns 
have been raised regarding pathogenicity. Furthermore, these vectors too can cause 
insertional mutagenesis by randomly integrating within the host genome.         
Adenoviral vectors were initially derived from adenovirus type 5 and can be 
propagated in high titres. Compared to their retroviral and lentiviral counterparts, 
these vectors consist of a large 36 kb genome which enables them to carry and 
deliver larger amounts of DNA. Adenoviral vectors have been used in the treatment 
of patients with solid tumors [37]. They also have the potential to be used in the 
treatment of diabetes and HIV infection [15, 16, 38]. Pseudotyping of these vectors 
however remains a challenge and like plasmids, adenoviral vectors too provide 
transient gene expression due to their episomal nature. Their ability to stimulate any 
pre-existing immunity is the principle concern regarding these vectors.  
Adeno-associated viral vectors are typically derived from adeno-associated virus 
serotype 2 (AAV2) and can be propagated in high titres. Owing to their non-
pathogenic nature and broad cellular tropism, these vectors are being looked upon 
more favourably with regard to their use in therapeutic applications. AAV vectors 
have been used in the treatment of patients with LCA [39]. They also have the 
potential to be used in the treatment of haemophilia B and liver cancer [8, 40]. Unlike 
adenoviral vectors, these vectors can be pseudotyped; however their small genome 
restricts the amount of DNA that can be delivered. Transient gene expression and 
the ability to stimulate any pre-existing immunity are the major disadvantages 





1.3 Challenges Associated with Gene Therapy 
It can be inferred from the previous section that a 100% perfect gene delivery 
approach is currently not in existence and whilst some approaches consist of unique 
flaws, a majority of them are associated with common technical issues. Whilst 
concerns regarding immunotoxicity, phenotoxicity (caused by the over-expression of 
a transgene) and horizontal/vertical transmission (the transfer of transgenes to other 
individuals/offspring) have been raised in the past, this section focuses on the major 
complications associated with ex vivo gene therapy, namely insertional mutagenesis 
and transgene silencing. 
  
1.3.1 Insertional Mutagenesis 
As discussed previously, retroviral and lentiviral vectors have the ability to induce 
persistent gene expression, which is ideal for therapeutic purposes. However, they 
do so by integrating within the host genome, a phenomenon referred to as random 
integration. Random integration results in insertional mutagenesis, which in turn can 
lead to tumorigenesis. For example, the success of the ex vivo gene therapy trial that 
enabled patients with SCID-X1 to successfully produce functional T-cells and NK 
cells, was overshadowed by the development of leukaemia in certain individuals. 
This was later attributed to the integration of the retroviral vector and its subsequent 
activation of the proto-oncogene LMO2 [41]. A similar incident was also reported in a 
patient treated for WAS [33]. The activation of LMO2 was attributed to the long 
terminal repeats (LTRs) found in both retroviral and lentiviral vectors as they contain 
enhancers and promoters capable of activating proto-oncogenes. The activation of 
proto-oncogenes as a result of retroviral and lentiviral vector integration has also 
been reported in patients treated for X-CGD and β-thalassaemia-based anaemia 
respectively [32, 35]. 
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1.3.2 Transgene Silencing 
When compared with retroviral and lentiviral vectors, adenoviral and AAV vectors 
hardly undergo random integration as they are almost entirely episomal in nature. 
The same holds true for plasmids delivered by non-viral systems. In relatively 
quiescent tissues (liver, brain, heart, muscle) episomal existence has no 
disadvantage. In rapidly dividing cells (HPCs) however, these vectors are eliminated, 
and as a result therapeutic benefits are lost over time. Whilst it would seem that 
random integration does have its advantages, studies have revealed that integrated 
vectors themselves lose their expression over time and upon cellular differentiation 
as they are subjected to silencing phenomena attributed to epigenetic modifications 
[42-45]. Epigenetic modification is a general term used to describe changes in 
histone proteins as a result of acetylation, methylation, phosphorylation and 
ubiquitination. Histones play a pivotal role in the packaging and structural 
organization of eukaryotic DNA and due to such modifications, genomic regions that 
were euchromatin (loosely packed – easy to transcribe) are transformed into 
heterochromatin (tightly packed – difficult to transcribe). Upon the death of a patient 
who was treated for X-CGD, it was found that although 60% of transplanted 
granulocytes contained the therapeutic gene, only 10% did in fact express it [46]. 
Due to these complications there is a compelling need to develop techniques that 
enable the integration of a transgene within a defined genomic locus that not only 
permits persistent expression (i.e. resistant to transgene silencing) of the gene but 
does so without compromising genomic stability (i.e. lack of random integration). 





1.4 Transgene Delivery within a Pre-Defined Genomic Locus 
In this section we focus on a genomic locus that is regarded as a safe harbour and is 
well known for averting transgene silencing. The current techniques utilised in 
targeting this locus are also discussed. 
 
1.4.1 Adeno-Associated Virus Integration Site-1 
Among the different genomic sites tested, the adeno-associated virus integration site-
1 locus (AAVS1) is one of the few loci that have been successfully targeted. The 
AAVS1 (~ 4.1 kb) is located within the protein phosphatase 1, regulatory (inhibitor) 
subunit 12C (PPP1R12C) gene on human chromosome 19 (19q13.3-qter) where it 
completely encompasses exon 1 and a majority of intron 1 as well. Although the 
function of the PPP1R12C gene has yet to be clearly determined, its protein products 
are said to be involved in regulating the actin cytoskeleton through a myosin 
phosphatase activity [47]. Studies have revealed that the AAVS1 also serves as a 
specific integration site for AAV serotype 2 (AAV2), a human parvovirus that contains 
a single-stranded linear DNA genome [48, 49]. Unable to replicate in the absence of 
a helper virus, AAV2 enters a latent phase where it integrates its genome preferably 
at the AAVS1 [48, 50]. The integration event is facilitated by viral protein binding 
domains found in both the viral genome and within this locus [51].  
Owing to its open chromatin structure, the AAVS1 has been characterized as a 
transcription-competent environment. It also contains native insulators that enable an 
integrated gene to resist epigenetic silencing phenomena [52-54]. Since there are no 
known adverse effects resulting from the disruption of the PPP1R12C gene and the 
transcriptional competence of a gene integrated within this locus remains across 
diverse cell types, the AAVS1 is therefore regarded as a safe harbour for the 
integration of transgenes within the human genome [55].   
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1.4.2 AAV2 Technology 
The AAV2 contains a 4.7 kb linear single-stranded DNA genome that is flanked by 
two 145 bp inverted terminal repeats (ITRs). The genome consists of two ORF that 
express rep and cap proteins. An alternate promoter and splicing mechanism 
enables the rep gene to express four different proteins (Rep78, Rep68, Rep52 and 
Rep40). Each ITR contains a rep-binding site (RBS) and a terminal resolute site 
(TRS) that act as substrates for Rep78/68 and it has been revealed that domains of 
similar homology are found within the AAVS1 as well.  
During viral integration, Rep78/68 bind to the ITRs and nick the TRS, a similar event 
is thought to take place within the AAVS1 as well. Whilst it would seem that the ITRs 
are essential for the integration event, studies have revealed that a 138 bp p5 
integration efficiency element (p5IEE) may be involved as well [56]. The complete 
mechanism regarding the integration event is not clearly understood.  
However, by using these viral proteins and integration elements, the AAVS1 has 
been successfully targeted at various efficiencies in human somatic cells [57-60]. 
Furthermore, by inserting the ITRs and the Rep genes into baculoviral vectors, our 
lab previously demonstrated that upon transduction of human embryonic stem cells 
(hESCs),  the resulting baculovirus-AAV hybrid system induced persistent transgene 
expression [61]. The occurrence of AAVS1-directed integration however was not 
confirmed in this study. A plasmid transfection-based AAV2 technology was later 
successful in achieving persistent transgene expression in hESCs, although the 
AAVS1-directed integration efficiency was as low as 4.16% [45]. 
 
1.4.3 Zinc-Finger Nucleases 
ZFNs are significant tools utilised in manipulating the genomes of various species 
[62-64]. These compounds are engineered by linking zinc-finger proteins (DNA-
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binding domains) with a nuclease domain (DNA-cleavage domain), typically the FokI 
endonuclease.  
When two dissimilar ZFN monomers come into close proximity with one another 
(heterodimer) and bind to a defined genomic site (pre-determined by their zinc-finger 
proteins), an active nuclease complex is formed which induces cleavage at this site, 
resulting in a double-strand break (DSB).  Once a DSB occurs, depending on the 
type of DNA-repair mechanism involved, one of three processes, either (i) non-
homologous end-joining, (ii) homology-directed repair incorporating endogenous 
DNA or (iii) homology-directed repair incorporating exogenous DNA could be initiated 
[65]. Non-homologous end-joining does not require a template strand and is hence 
error-prone which may result in gene knockdown. Homology-directed repair however 
requires a template strand, which can either be provided by a sister chromatid or an 
exogenous donor that contains regions of homology encompassing and flanking the 
DSB. The use of an exogenous donor for instance may result in gene editing or even 
gene augmentation.  
When using ZFNs to target the AAVS1, transgene integration efficiencies ranging 
from 33 – 61% were achieved in hESCs and human induced pluripotent stem (iPS) 
cells [66]. ZFNs are however capable of inducing off-target DSB which results in 
genotoxicity and cytotoxicity [67]. 
  
1.4.4 Transcription Activator-Like Effector Nucleases 
Transcription activator-like effectors (TALEs) are naturally occurring transcription 
factors used by plant pathogens to regulate host genomes and like ZFNs they too 
can be linked with a FokI nuclease domain [68, 69].  
Unlike zinc-finger proteins which determine the genomic binding site for ZFNs, 
TALEs consist of tandem repeats of amino acid units which define the binding site for 
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TALENs. Each repeat that of which consists of ~ 34 amino acids is very similar to 
one another except for two variable amino acids at position 12 and 13 referred to as 
the repeat variant di-residue (RVD) [70]. Since these variants recognize a specific 
nucleotide unlike zinc-finger modules which recognize a triplet of nucleotides, greater 
flexibility is achieved when designing TALENs. The mechanism of TALENs is 
identical to that of ZFNs in that they form heterodimers (active nuclease complex) 
which induce cleavage at a pre-defined genomic site resulting in a DSB. Once a DSB 
occurs, either non-homologous end joining or homology-directed repair can be 
incorporated to obtain the desired genetic modification.  
When using TALENs to target the AAVS1, transgene integration efficiencies ranging 
from 43 – 77% were achieved in hESCs and human iPS cells [71]. The ability of 
TALENs to induce off-target DSB has not yet been fully assessed and the large size 











2. Aim of Study 
Human embryonic stem cells (hESCs) have the unique ability to generate virtually 
any differentiated cell type and in the optimum culture conditions can be directed to 
do so in vitro [72-77]. In the context of regenerative medicine, progenies derived from 
these human pluripotent cells can be used as transplantable cells for cell-based 
therapy [78-81]. However, ex vivo gene therapy requires that these cells be 
genetically modified prior to transplantation, meaning that they must stably express a 
therapeutic gene which can either cure or alleviate the disease being treated. 
However, as discussed previously insertional mutagenesis and transgene silencing 
complicate this form of therapy.  
The adeno-associated integration site-1 locus (AAVS1) is regarded as a safe harbour 
for the integration of therapeutic genes and also as a transcription-competent 
environment [52-55]. By conducting research on AAV2 technology, ZFNs and 
TALENs, efforts have been made to overcome insertional mutagenesis and 
transgene silencing. When utilising AAV2 technology, AAVS1-directed transgene 
integration has been achieved in hESCs albeit at a very low efficiency [45]. Although 
the integration efficiency is not an issue when using either ZFNs or TALENs, the 
induction of off-target DNA double-strand breaks presents a high risk of genomic 
instability [66, 67, 71]. These factors hinder the use of these technologies in ex vivo 
gene therapy.  
Therefore, this study attempts to develop a site-specific transgene integration system 
which is not only safe but can also direct transgenes towards the AAVS1 at high 
efficacy. In order to achieve this, a two-step genetic modification process was 
adopted. Conventional homologous recombination was first performed to introduce 
heterospecific loxP sites into the AAVS1 (Figure 2.1A). This was followed by Cre 
recombinase-mediated cassette exchange (RMCE) which enabled the integration of 
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a floxed transgene in a site-specific manner (Figure 2.1B). Recombinant baculoviral 
vectors were used for the delivery of the recombinase and the transgene donor. 
RMCE incorporates the well-renowned bacteriophage-derived Cre/loxP system, 
which consists of two components; the Cre recombinase protein and short DNA 
sequences known as loxP sites. Cre has the ability to catalyse genomic 
recombination events between these sites [82-86]. However, loxP sites do not exist 
within the human genome and therefore need to be introduced by homologous 
recombination. Once a cell line containing loxP-docking sites at the AAVS1 is 
generated, recombination between this locus and a floxed transgene can be 
mediated by Cre. The use of heterospecific loxP sites as opposed to wild-type sites 
prevents intra-molecular recombination, ensuring that only unidirectional transgene 
integration is permitted within the AAVS1. In short, RMCE is a biphasic transgene 
integration strategy incorporating both homologous recombination and site-specific 
recombination.     
Baculoviral vectors differ from animal viral vectors in that they are derived from an 
insect virus, typically the Autographa californica multiple nuclear polyhedrosis virus 
(AcMNPV). Their 134 kb genome, which is the largest among viral vectors enables 
them to carry inserts of up to 38 kb [87]. More importantly, these vectors present a 
broad tropism towards mammalian cells, and since they neither replicate in the cells 
nor integrate within the genome they demonstrate both efficiency and safety with 
regard to gene delivery [88-90]. Baculoviral vectors have the potential to be used in 
vivo in the treatment of glioblastoma and gastric cancer and also in promoting 
antiangiogenesis [91-93]. Furthermore, transplantable cells modified by these vectors 
have the potential to be used in the treatment of lung cancer and in bone engineering 
[94, 95]. Unlike their adenoviral and AAV counterparts, there is no pre-existing 
immunity directed against baculoviruses [96]. Inactivation in human sera due to the 
complement system is the major drawback associated with these vectors. However, 
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by identifying ways in which to inhibit the complement system and by genetically 
modifying the viral envelope to circumvent serum inactivation, measures have been 
taken to address this issue [97, 98].              
Although the primary objective of this study was to develop a novel approach for 
generating transgenic hESCs for ex vivo gene therapy, the feasibility of this 
technique was initially examined on HeLa cells as their robust nature enables easy 
genome manipulation. In short, this thesis describes a novel approach for attaining 
AAVS1-directed transgene integration through a baculoviral vector-mediated RMCE 
(BV-RMCE) approach. The ability of a baculovirus-zinc-finger nuclease (BV-ZFN) 
system to mediate homologous recombination in the absence of drug selection is 


































Figure 2.1: Schematic representation of BV-RMCE. (A) Homologous recombination 
to introduce heterospecific loxP sites into the AAVS1. The targeting construct 
contains homologous arms encompassing the locus and flanking chromosomal 
regions. (B) BV-RMCE to integrate a transgene within the AAVS1. The transgene is 
flanked by the same heterospecific loxP sites which permit cassette exchange within 
the already modified AAVS1 in the presence of Cre recombinase. (AA.., ..VS1 depict 
a disrupted AAVS1)   
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3. Materials and Methodology 
3.1 Vector Construction and Baculovirus Propagation 
3.1.1 Plasmid Construction 
To target the AAVS1 by homologous recombination, two plasmids were constructed. 
To construct pBS-PGK-neo-lox, using the QuikChange® II XL Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) a two base mutation was induced 
within one of the loxP sites present in PGKneotpAlox2 (Adgene, Cambridge, MA, 
USA). The 8 bp central spacer element of a loxP site reads ATGTATGC. The 
mutation converts this sequence into AAGTATCC and this site is now referred to as 
lox2722. A 4 kb left homologous arm and a 3 kb right homologous arm pertaining to 
the PPP1R12C gene was amplified from genomic DNA isolated from H1 hESCs and 
cloned into pCR®-BluntII-TOPO® (Invitrogen, Carlsbad, CA, USA) independently. The 
two arms were then excised using ClaI/XhoI and SacI/SacII respectively and cloned 
into the mutated PGKneotpAlox2 on either side of a fragment containing the lox2722 
site, the PGK promoter, the neomycin resistance gene (neo) and the loxP site. To 
construct pBS-EF1α-EGFP-neo-lox, a 2.1 kb fragment containing the EF1α promoter, 
the EGFP gene and a SV40 poly(A) tail was amplified from a previous pFastBac1 
construct and cloned into the mutated PGKneotpAlox2 using EcoRI [61]. This gave 
rise to an intermediate vector, pBS-EF1α-EGFP-neo. Using NotI/ClaI, a 4.9 kb 
fragment containing the lox2722 site, the EF1α promoter, the EGFP gene, the PGK 
promoter, the neo gene and the loxP site was then excised from pBS-EF1α-EGFP-
neo and cloned into pBS-PGK-neo-lox, replacing the existing 2.7 kb fragment 
containing the lox2722 site, the PGK promoter, the neo gene and the loxP site. 
Primers used in mutating the loxP site into a lox2722 site and those used in 




3.1.2 Recombinant Baculoviral Vector Construction 
To propagate recombinant baculoviruses for BV-RMCE, three viral vectors were 
constructed. To construct pFB-EF1α-Cre, using HindIII the 0.7 kb EGFP ORF 
(previous pFastBac1 construct) was replaced with a 1 kb Cre ORF which was 
amplified from pBS185 (Adgene). To construct pFB-EF1α-EGFP-hyg-lox, the 
aforementioned 4.9 kb fragment containing the lox2722 site, the EF1α promoter, the 
EGFP gene, the neo gene and the loxP site was excised from pBS-EF1α-EGFP-neo 
and cloned into pFastBac1 using NotI/SalI. This resulted in an intermediate vector, 
pFB-EF1α-EGFP-neo-lox. A 1.6 kb fragment containing the SV40 promoter, the 
hygromycin resistance gene (hyg) and a SV40 poly(A) tail was amplified from 
pDsRed-Monomer-Mem Hyg (Clontech, Mountain View, CA, USA) and using 
BlpI/PflMI cloned into pFB-EF1α-EGFP-neo-lox, replacing the 1.3 kb fragment 
containing the PGK promoter and the neo gene. To construct pFB-EF1α-HSVTK-
hyg-lox, a 1.4 kb fragment containing the HSVtk suicide gene and a SV40 poly(A) tail 
was amplified from a previous construct and using AfeI/SbfI cloned into pFB-EF1α-
EGFP-hyg-lox, replacing the 1 kb fragment containing the EGFP gene and the SV40 
poly(A) tail [91].  
To propagate recombinant baculoviruses for BV-ZFN technology, two viral vectors 
were constructed. To construct pFB-EF1α-ZFN-IRES, a 0.9 kb cDNA fragment 
pertaining to the right and left ZFNs (Invitrogen) was amplified and cloned into 
pFastBac1 using NotI/XbaI and KpnI/HindIII respectively. The 1.1 kb EF1α promoter 
was amplified from pFB-EF1α-EGFP-hyg-lox and using BamHI/NotI cloned into this 
construct. The right and left ZFN ORFs were separated by a 0.6 kb IRES which was 
amplified from pIRES (Clontech) and cloned using XbaI/KpnI. To construct pFB-
EF1α-EGFP-AAVS1, a 2.1 kb fragment containing the EF1α promoter, the EGFP 
gene and a SV40 poly(A) tail was amplified from pFB-EF1α-EGFP-hyg-lox and using 
EcoRI/SalI cloned into pZDonor-AAVS1 (Sigma-Aldrich, St. Louis, MO, USA)  which 
22 
 
contains a 0.8 kb left and right homologous arm pertaining to the PPP1R12C gene. 
The 3.8 kb fragment containing the left homologous arm, the EF1α promoter, the 
EGFP gene, the SV40 poly(A) tail and the right homologous arm was amplified and 
cloned into pFastBac1 using SpeI/SphI.   
 
3.1.3 Baculovirus Propagation  
Recombinant baculoviruses were propagated in Sf9 cells (Invitrogen). Cells were 
cultured in Sf-900 II SFM (Invitrogen) and maintained at 27oC. The viral vectors were 
all based on a pFastBac1 backbone (Invitrogen). pFastBac1 is a donor plasmid that 
allows the gene of interest to be transferred into a baculovirus shuttle vector (bacmid) 
via transposition. The initial P1 baculovirus stock was obtained by transfecting Sf9 
cells with bacmid according to the Bac-to-Bac® Baculovirus Expression System 
(Invitrogen). A high-titre P2 virus stock was obtained by infecting 1 x 107 cells with 
200 µl of P1 virus. Three-four days later the Sf-900 II SFM containing viral particles 
was centrifuged at 500 x g and the supernatant stored at 4oC in the dark. A plaque 










3.2 Genetic Modification of Human Cell Lines 
3.2.1 HeLa Cells  
HeLa cells (ATTC, Manassas, VA, USA) were cultured in DMEM (Invitrogen) 
supplemented with 10% FBS (HyClone, Logan, UT, USA), L-glutamine (2mM, 
Invitrogen) and 1% PS (Invitrogen). Cells were maintained in a 5% CO2 humidified 
incubator at 37oC. For homologous recombination, 2 x 105 HeLa cells were seeded in 
one well of a 6-well plate. Cells were transfected the following day with 2 μg of BsaI 
linearized pBS-PGK-neo-lox at a 1:3 DNA to reagent ratio (FuGENE® HD 
Transfection Reagent, Roche, Mannheim, Germany). Twenty-four hours later the 
transfected cells were seeded in 10-cm dishes at a density of 1 x 104 cells/dish. 
Another 24 hours later (48 hours post transfection) G418 selection (1000 μg/ml, 
Invitrogen) in DMEM was started. The optimum G418 concentration was determined 
by performing a kill curve ranging from 100-1200 μg/ml. Medium was changed every 
3 days for 2 weeks until resistant colonies propagated. 
For BV-RMCE, 5 x 104 loxP-HeLa45 cells were seeded in one well of a 24-well plate. 
Cells were co-transduced the following day with BV-EF1α-Cre at a MOI of 100 and 
with BV-EF1α-EGFP-hyg-lox at either a MOI of 10, 50 or 100. Forty-eight hours later 
the transduced cells were seeded in 10-cm dishes at a density of 1 x 104 cells/dish. 
Twenty-four hours later (72 hours post co-transduction) hygromycin B selection (200 
μg/ml, A.G. Scientific, San Diego, CA, USA) in DMEM was started. The optimum 
hygromycin B concentration was determined by performing a kill curve ranging from 
100-600 μg/ml. Medium was changed every 3 days for 2 weeks until resistant 
colonies propagated. 
Each colony that propagated through either G418 or hygromycin B selection was 
transferred to one well of a 96-well plate and allowed to undergo clonal expansion in 
selection medium for an additional 2 weeks. 
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For BV-ZFN technology, 5 x 104 HeLa cells were seeded in one well of a 24-well 
plate. Cells were either transduced the following day with BV-EF1α-EGFP-AAVS1 at 
a MOI of 100 or co-transduced with BV-EF1α-ZFN-IRES and BV-EF1α-EGFP-
AAVS1 each at a MOI of 100. Transduced cells were routinely cultured with flow 
cytometric analysis performed at the relative time points. 
 
3.2.2 Human Embryonic Stem Cells  
H1 hESCs (WiCell, Madison, WI, USA) were cultured in mTeSRTM1 medium 
(StemCell Technologies, Vancouver, BC, Canada) according to the protocol 
described in the technical manual: “Maintenance of Human Embryonic Stem Cells in 
mTeSRTM1”. Feeder-independent conditions were applied by coating the culture 
plates with MatrigelTM, a hESC-qualified matrix, (BD Biosciences, Bedford, MA, 
USA). Cells were maintained in a 5% CO2 humidified incubator at 37
oC. For 
homologous recombination, 4 days following sub-culture 2 x 106 hESCs in one well 
of a 6-well plate were transfected with either 2 μg of BsaI linearized pBS-PGK-neo-
lox or pBS-EF1α-EGFP-neo-lox at a 1:3 DNA to reagent ratio (FuGENE® HD 
Transfection Reagent, Roche). Twenty-four hours later the transfected cells were 
seeded in a Matrigel-coated 10-cm dish. Another 24 hours later (48 hours post 
transfection) G418 selection (50 μg/ml, Invitrogen) in mTeSR1 medium was started. 
The optimum G418 concentration was determined by performing a kill curve ranging 
from 25-400 μg/ml. Medium was changed daily for 3 weeks until resistant colonies 
propagated.         
For BV-RMCE, 4 days following sub-culture 2 x 106 loxP-hESC2 cells in one well of a 
6-well plate were transduced with BV-EF1α-Cre at a MOI of 100. Twenty-four hours 
later the medium was changed and cells were again transduced with either BV-
EF1α-EGFP-hyg-lox or BV-EF1α-HSVtk-hyg-lox at a MOI of 100. Another 24 hours 
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later the transduced cells were seeded in a Matrigel-coated 10-cm dish. Hygromycin 
B selection (25 μg/ml, A.G. Scientific) in mTeSR1 medium was started the following 
day (48 hours following the second transduction). The optimum hygromycin B 
concentration was determined by performing a kill curve ranging from 10-200 μg/ml. 
Medium was changed daily for 4 weeks until resistant colonies propagated.              
Each colony that propagated through either G418 or hygromycin B selection was 
transferred to one well of a Matrigel-coated 6-well plate and allowed to undergo 
clonal expansion without drug selection. One week later each clone was sub-cultured 
at a 1:6 ratio.  
Using the DNeasy® Blood & Tissue Kit (Qiagen, Hilden, Germany), DNA of both 
HeLa and hESC clones was isolated and screened for AAVS1 modification by PCR 
























3.3 Detection of AAVS1 Modifications 
3.3.1 PCR Genotyping 
Both homologous recombination and RMCE events were detected by PCR 
genotyping. All PCR amplifications were performed using the following parameters: 
an initial denaturation step at 95oC for 5 minutes followed by 30 cycles at 98oC for 20 
seconds, 65oC for 15 seconds and 72oC for 2 minutes with a final extension step at 
72oC for 5 minutes. Amplified products were analyzed on a 1% agarose gel.  
 
3.3.2 Southern Blot Analysis 
Genomic DNA (10 µg) was digested overnight with either ApaLI or NcoI. The 
digested DNA was loaded on to a 1% agarose gel and electrophoresis was 
performed for 16 hours at 25 V. Using the iBlot® Dry Blotting System (Invitrogen), the 
DNA was then transferred on to a positively charged nylon membrane. The 
membrane was washed twice with 1.5 M NaCl/0.5 N NaOH denaturing solution and 
air-dried. UV cross-linking was performed at 120 mJ/cm2. The membrane was first 
pre-hybridized for 2 hours and then hybridized overnight with DIG Easy Hyb (Roche). 
DIG-labelled probes were synthesised using the PCR DIG Probe Synthesis Kit 
(Roche). Following hybridization the membrane was first washed twice with 2X 
SSC/0.1% SDS at room temperature and then twice with 0.5X SSC/0.1% SDS at 
68oC. Blocking was performed using the DIG Wash and Block Buffer Set (Roche). 
The membrane was then incubated with an anti-DIG antibody (DIG DNA Labelling 
and Detection Kit, Roche) that was detected by CDP-Star, ready-to-use (Roche). 
Primers used in PCR genotyping and those used in synthesising DIG-labelled probes 




3.4 Human Embryonic Stem Cell Differentiation 
3.4.1 Embryoid Body Derivation 
On the day of sub-culture, mTeSR1 medium was replaced and hESCs were 
transferred to a 10-cm Petri dish (suspension culture) and maintained in DMEM/F12 
(Invitrogen) supplemented with 20% KnockOut™ Serum Replacement (Invitrogen), 
L-glutamine (1mM, Invitrogen) with trace amounts of β-mercaptoethanol solution, 1X 
NEAA (Invitrogen) and 1% PS (Invitrogen). Medium was changed every alternate day 
for 2 weeks. 
 
3.4.2 Neurosphere, Glial Cell and Neuron Derivation  
For neurosphere derivation, on the day of sub-culture mTeSR1 medium was 
replaced and hESCs were transferred to a 10-cm Petri dish (suspension culture) and 
maintained in DMEM/F12 (Invitrogen) supplemented with B-27® Supplement Minus 
Vitamin A (Invitrogen), L-glutamine (2mM, Invitrogen), bFGF (20 ng/ml, PeproTech, 
Rocky Hill, NJ, USA), EGF (20 ng/ml, PeproTech) and 1% PS (Invitrogen). Medium 
was changed every alternate day for 4 weeks. For dissociation, neurospheres were 
incubated with StemPro® Accutase® Cell Dissociation Reagent (Invitrogen) for 10 
minutes at room temperature. Cells were then filtered through a 100 µm cell strainer 
and seeded in a Matrigel-coated (Basement Membrane Matrix, BD Biosciences) 6-
well plate. Medium was changed every alternate day. For glial cell derivation, 
dissociated neural stem cells (NSCs) were seeded in a CELLstart™-coated 
(Invitrogen) 6-well plate and maintained in DMEM/F12 (Invitrogen) supplemented 
with N-2 Supplement (Invitrogen), B-27® Serum-Free Supplement (Invitrogen), L-
glutamine (2mM), 1X NEAA (Invitrogen) and 1% PS. Medium was changed every 
alternate day for 2 weeks. For neuron derivation, dissociated NSCs were seeded in a 
poly-D-lysine and laminin-coated (10 µg/ml, Sigma-Aldrich) 6-well plate and 
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maintained first in neurosphere medium. This medium was changed every alternate 
day for 4 weeks. Cells were then maintained in Neurobasal® medium (Invitrogen) 
supplemented with B-27® Serum-Free Supplement, 1X NEAA, L-glutamine (2mM), 
Shh (200 ng/ml, PeproTech), FGF8 (50-100 ng/ml, PeproTech) and 1% PS for 10 
days. Shh and FGF8 were then replaced with BDNF (20 ng/ml, PeproTech), GDNF 
(20 ng/ml, PeproTech), TGF-β3 (1 mM, PeproTech) and dcAMP (1 mM, Sigma-
Aldrich). Cells were maintained in this medium for 4 weeks.  
 
3.4.3 Mesenchymal Stem Cell Derivation               
Embryoid bodies were derived as previously described. Ten days following their 
derivation, embryoid bodies were seeded in a 0.1% gelatin-coated (Sigma-Aldrich) 
10-cm dish. Three days following seeding, adherent embryoid bodies were 
maintained in DMEM (Invitrogen) supplemented with 10% FBS (Hyclone), L-
glutamine (2mM, Invitrogen), 1X NEAA (Invitrogen) and 1% PS (Invitrogen). Medium 
was changed every 3 days until cells that outgrew from these embryoid bodies 
displayed fibroblastic morphology. These outgrowths were then transferred to a 0.1% 
gelatin-coated 24-well plate and expanded. 
 
3.4.4 Dendritic Cell Derivation  
OP9 cells (ATCC) were cultured in α-MEM (Invitrogen) supplemented with 20% FBS 
(Hyclone). 0.1% gelatine-coated (Sigma-Aldrich) 10-cm dishes were used for this 
purpose. Four days following sub-culture half of the medium was replaced with fresh 
medium. Another 4 days later, cells were maintained in α-MEM supplemented with 
10% of FBS and MTG (100μM, Sigma-Aldrich). On the day of sub-culture mTeSR1 
medium was replaced and hESCs were transferred to a 10-cm dish containing over-
confluent OP9 cells (co-culture) and maintained in the medium previously described. 
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Half of the medium was changed every alternate day for 8 days. The co-culture was 
then dissociated by incubation with collagenase type IV (Invitrogen) and trypsin 
(Invitrogen). Cells were filtered through a 70μM cell strainer and transferred to an 
anti-adhesive polymer-coated (pHEMA, Sigma-Aldrich) T75 flasks (suspension 
culture) and maintained in α-MEM supplemented with 10% FBS, MTG (100μM) and 
GMCSF (100 ng/ml, PeproTech). Half of the medium was changed every 3 days for 
10 days. Dead cells were then removed using 25% Percoll solution (Sigma-Aldrich) 
and viable cells were maintained in StemSpan® SFEM (StemCell Technologies) 
supplemented with Lipid Mixture 1 (Sigma-Aldrich), GMCSF (100 ng/ml), and IL-4 
(100 ng/ml, Peprotech). Half of the medium was changed every 4 days for 2 weeks.  
































3.5 Characterization of Human Embryonic Stem Cells and 
Differentiated Cell Progenies 
3.5.1 Immunostaining 
Immunostaining was performed to detect surface markers in hESCs. Cells were fixed 
with 4% PFA for 20 minutes and then blocked with 1% BSA/PBS for 45 minutes. 
Both steps were performed at room temperature. Primary antibodies tested include 
anti-SSEA-4, anti-Tra-1-60 and anti-Tra-1-81 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Antibody incubation was performed overnight at 4oC. Incubation 
with a PE-conjugated secondary antibody (Santa Cruz Biotechnology) was 
performed for 1 hour at room temperature in the dark. hESCs were also stained to 
detect intra-cellular markers. Cells were fixed as previously described but blocking 
and permeabilization was performed in one step with 0.3% Triton X-100/1% 
BSA/PBS for 45 minutes at room temperature. Primary antibodies tested include anti-
Oct-3/4, anti-SOX2 and anti-Nanog (Human Embryonic Stem Cell Marker Antibody 
Panel Plus, R&D Systems, Minneapolis, MN, USA). Antibody incubation was 
performed overnight at 4oC. Incubation with a TR-conjugated secondary antibody 
(Abcam, Cambridge, MA, USA) was performed for 1 hour at room temperature in the 
dark. Ectodermal-derived cells were stained to detect intra-cellular markers. Cells 
were fixed with 4% PFA for 15 minutes and then permeabilized with 0.3% Triton X-
100/PBS for 5 minutes. Both steps were performed at room temperature. Blocking 
with 1%BSA/PBS was performed for 1 hour at room temperature. Primary antibodies 
tested include anti-Nestin (Abcam), anti-GFAP (Sigma-Aldrich) and anti-βIII tubulin 
(Promega, Madison, WI, USA). Antibody incubation was performed overnight at 4oC. 
Incubation with a Texas Red-conjugate secondary antibody (Abcam) was performed 




3.5.2 RT-PCR Analysis   
Total RNA was extracted with TRIzol® (Invitrogen) and cDNA was synthesized using 
the SuperScript® III First-Strand Synthesis System (Invitrogen). All RT-PCR 
amplifications were performed using the following parameters: an initial denaturation 
step at 95oC for 3 minutes followed by 30 cycles at 95oC for 30 seconds, 55oC for 30 
seconds and 72oC for 1 minute with a final extension step at 72oC for 5 minutes. 
Amplified products were analyzed on a 2% agarose gel. 
Primers used in RT-PCR analysis are listed in the Appendix. 
 
3.5.3 Flow Cytometric Analysis 
Cells were first re-suspended in 5%FBS/PBS. For MSCs, primary antibodies tested 
include PE-conjugated anti-CD24, anti-CD34, anti-CD45, anti-CD44, anti-CD73, anti-
CD90, anti-CD105 and anti-CD166 (BD Pharmingen, San Diego, CA, USA). APC-
conjugated anti-HLA ABC and FITC-conjugated anti-HLA DRQP were also tested, 
along with their respective isotypes (BD Pharmingen). Antibody incubation was 
performed for 30 minutes at 4oC in the dark. Anti-HLA DRQP stained cells were 
washed with PBS and further incubated with a TRITC-conjugated secondary 
antibody (Sigma-Aldrich) for 30 minutes at 4oC in the dark. For DCs, primary 
antibodies tested include APC-conjugated anti-CD11c, anti-CD40, anti-CD45, anti-
CD86, anti-CD209 and their respective isotypes (BD Pharmingen). Antibody 
incubation was performed as previously described. Stained cells were analyzed 
using a FACSCaliburTM flow cytometer (BD Biosciences). When analyzing hESCs, 





3.6 BV-RMCE Functional Studies  
3.6.1 In Vitro Tumor Killing Assay 
Neurospheres were first derived from wild-type hESCs and TK-hESCs. These 
spheres were then dissociated and seeded in a Matrigel-coated (BD Biosciences) 6-
well plate. Upon reaching 80% confluency, wild-type NSCs were transduced with BV-
EF1α-HSVTK-hyg-lox at a MOI of 100. Twenty-four hours later, U87 human glioma 
cells (ATCC) were seeded in a Matrigel-coated 96-well plate at a density of 1 x 103 
cells/well and maintained in neurosphere medium. NSCs were also seeded at a 
density of 1 x 103 cells/well in the same wells containing the U87 cells (co-culture). 
Another 24 hours later neurosphere medium containing GCV (20 µM, Invivogen, San 
Diego, CA, USA) was added to the cells. Medium was changed every alternate day 
for 1 week. Using CellTiter 96® AQueous One Solution (Promega) a cell viability assay 
was performed and absorbance was measured using a Benchmark PlusTM microplate 
spectrophotometer (Bio-Rad, Hercules, CA, USA). 
 
3.6.2 In Vitro Migration Assay   
Migration ability of NSCs, was tested using the BD FalconTM HTS FluoroBlokTM 96-
Multiwell Insert System (8 μm pore size, BD Biosceinces). First, U87 cells were 
seeded in the bottom receiver plate at a density of 6.4 x 104 cells/well and maintained 
in Opti-MEM® I (Invitrogen). NSCs were then labelled with Calcein-AM (5 μg/ml, 
AnaSpec, Fremont, CA, USA). This was done by incubating the cells in neurosphere 
medium containing calcein for 10 minutes. Cells were then washed thrice with 
medium and maintained overnight in Opti-MEM. Twenty-four hours later, labelled 
NSCs were seeded in the inserts at a density of 2.5 x 104 cells/insert and maintained 
in Opti-MEM. Cells in both the receiver (U87 cells) and the inserts (NSCs) were then 
incubated together in a 5% CO2 humidified incubator for 24 hours at 37
oC. Using a 
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GENios ProTM microplate reader (Tecan, Männedorf, Switzerland), we measured the 
fluorescence emitted from the top (corresponding to non-migrating cells) and the 


















4. Experimental Results 
4.1 Homologous Recombination at the AAVS1  
The use of the Cre/loxP system for the integration of transgenes within a specific 
locus initially requires the integration of loxP-docking sites within that particular locus 
by homologous recombination. To target the AAVS1 on chromosome 19 (19q13.42), 
a targeting vector pBS-PGK-neo-lox which contains a floxed neomycin resistance 
marker flanked by a left and right arm corresponding to ~ 7 kb of homology of the 
PPP1R12C gene was constructed. Exon 1 (337 bp) of the gene is present in the left 
arm whilst exon 2 (131 bp) and 3 (119 bp) are present on the right. The AAVS1 
begins 424 bp upstream of the 5’ end of exon 1 and ends 3.35 kb downstream of the 
3’ end. The region that was targeted is found ~ 1.9 kb downstream of the 3’ end of 
exon 1 (19:60318479 – 19:60318512) and can also be considered as intron 1.  
  
4.1.1 Generation of a loxP-HeLa Cell Line  
Following transfection with pBS-PGK-neo-lox, a plethora of HeLa colonies 
propagated through G418 selection. Of these colonies, fifty were randomly selected 
and expanded and their DNA was subjected to PCR genotyping by using a primer 
specific for the PGK promoter present in the pBS-PGK-neo-lox construct and a 
primer specific for chromosome 19 downstream of the 3` end of the right homologous 
arm (Figure 4.1A). The amplification of a 3.3 kb fragment confirmed the successful 
integration of a floxed neomycin cassette within the AAVS1 by homologous 
recombination. From this analysis, eighteen clones were identified as containing a 
modified AAVS1 (Figure 4.2A, Table 4.1). For further confirmation, using a probe 
specific for chromosome 19, Southern blot analysis was performed on five randomly 
selected loxP-HeLa clones (Clones #4, #12, #22, #34 and #45). The detection of a 
9.8 kb fragment confirmed a modified AAVS1, whereas detection of a 7.1 kb 
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fragment confirmed an intact locus (wild-type) (Figure 4.1B). Fragments of both 
sizes were detected thereby identifying the clones to be heterozygous for a modified 
AAVS1 (Figure 4.2B). loxP-HeLa Clone #45 (loxP-HeLa45) was randomly selected 
as the master loxP-HeLa cell line and subjected to further downstream studies. 
 
4.1.2 Generation of a loxP-hESC Line 
Following three independent transfection experiments with pBS-PGK-neo-lox, a total 
of thirty-nine hESC colonies propagated through G418 selection. These colonies 
were expanded and their DNA was subjected to PCR genotyping by using a primer 
specific for the PGK promoter present in the pBS-PGK-neo-lox construct and a 
primer specific for chromosome 19 downstream of the 3` end of the right homologous 
arm (Figure 4.1A). The amplification of a 3.3 kb fragment confirmed the successful 
integration of a floxed neomycin cassette within the AAVS1 by homologous 
recombination. From this analysis, eleven clones were identified as containing a 
modified AAVS1 (Figure 4.3A, Table 4.2). For further confirmation, using a probe 
specific for chromosome 19, Southern blot analysis was performed on three 
randomly selected loxP-hESC clones (Clones #2, #5 and #6). The detection of a 9.8 
kb fragment confirmed a modified AAVS1, whereas detection of a 7.1 kb fragment 
confirmed an intact locus (wild-type) (Figure 4.1B). Fragments of both sizes were 
detected thereby identifying the clones to be heterozygous for a modified AAVS1 
(Figure 4.3B). loxP-hESC Clone #2 (loxP-hESC2) was randomly selected as the 
master loxP-hESC line and subjected to further downstream studies. 
To target the AAVS1 on chromosome 19 another targeting vector pBS-EF1α-EGFP-
neo-lox was constructed. This construct contained a floxed neomycin resistance 




Following transfection with pBS-EF1α-EGFP-neo-lox, eleven EGFP-hESC colonies 
propagated through G418 selection. These colonies were expanded and their DNA 
was subjected to PCR genotyping by using a primer specific for the EF1α promoter 
present in the pBS-EF1α-EGFP-neo-lox construct and a primer specific for 
chromosome 19 downstream of the 3` end of the right homologous arm (Figure 
4.1C). The amplification of a 4.2 kb fragment confirmed the successful integration of 
a floxed EGFP-neomycin cassette within the AAVS1 by homologous recombination. 
From this analysis, a single clone was identified as containing a modified AAVS1 


















Figure 4.1: Schematic representations for detection of homologous recombination. 
(A) Detection of a modified AAVS1 by PCR genotyping following its targeting with 
pBS-PGK-neo-lox. (B) Verification of a modified AAVS1 by Southern blot analysis. 
(C) Detection of a modified AAVS1 by PCR genotyping following its targeting with 






Figure 4.2: Detection of homologous recombination in HeLa cells. (A) PCR 
genotyping for detection of a modified AAVS1. loxP-HeLa clones were identified 
through amplification of a 3.3 kb fragment. Highlighted clones were analyzed by 
Southern blot. (B) Southern blot analysis to verify a modified AAVS1. Following 
digestion with ApaLI and hybridization, two fragments (7.1 kb and 9.8 kb) were 
detected in loxP-HeLa clones (Clones #4, #12, #22, #34 and #45) as opposed to the 
solitary fragment detected in wild-type HeLa cells. This result confirmed that the loxP-





Table 4.1: Efficiency of AAVS1 targeting in HeLa cells by homologous 
recombination 
No. of transfected cells 200,000
 
No. of G418 resistant colonies 50 
No. of correctly targeted clones identified by PCR genotyping 18 
No. of clones analyzed by Southern Blot 5 
No. of correctly targeted clones verified by Southern blot analysis 5 
HR frequency as verified by PCR genotyping  9 x 10-5 
Targeting efficiency as verified by PCR genotyping (%) 36 





















Figure 4.3: Detection of homologous recombination in hESCs. (A) PCR genotyping 
for detection of a modified AAVS1 when using pBS-PGK-neo-lox targeting construct. 
loxP-hESC clones were identified through amplification of a 3.3 kb fragment. 
Highlighted clones were analyzed by Southern blot. (B) Southern blot analysis to 
verify a modified AAVS1. Following digestion with ApaLI and hybridization, two 
fragments (7.1 kb and 9.8 kb) were detected in loxP-hESC clones (Clones #2, #5 and 
#6) as opposed to the solitary fragment detected in wild-type hESCs. This result 
confirmed that the loxP-hESC clones were heterozygous, containing one intact 
AAVS1 and one modified locus. (C) PCR genotyping for detection of a modified 
AAVS1 when using pBS-EF1α-EGFP-neo-lox targeting construct. loxP(EGFP)-hESC 





Table 4.2: Efficiencies of AAVS1 targeting in hESCs by homologous 
recombination 
pBS-PGK-neo-lox Exp 1 Exp 2 Exp 3 
No. of transfected cells 2,000,000 2,000,000 2,000,000 
No. of G418 resistant colonies 12 9 18 
No. of correctly targeted clones identified by 
PCR genotyping 
3 4 4 
No. of correctly targeted clones verified by 
Southern blot analysis 
3 nd nd 
HR frequency as verified by PCR genotyping  1.5x10-6 2.0x10-6 2.0x10-6 
Targeting efficiency as verified by PCR 
genotyping (%) 
25.00 44.44 22.22 
Mean targeting efficiency (%) ± SD 30.56 ± 12.11 
pBS-EF1α-EGFP-neo-lox  
No. of transfected cells 2,000,000 
No. of G418 resistant colonies 11 
No. of correctly targeted clones identified by 
PCR genotyping 
1 
HR frequency  5 x 10-7 
Targeting efficiency (%) 9.09 
Abbreviations: No., number; Exp, experiment; nd, not determined; HR, homologous 





4.2 Cre Recombinase-Mediated Cassette Exchange Using 
Baculoviral Vectors 
Once loxP-cell lines (loxP-HeLa45 and loxP-hESC2) were generated, they were 
subjected to BV-RMCE. For this purpose two baculoviral vectors were generated, 
one to express Cre recombinase (BV-EF1α-Cre) and the other the transgene donor 
(BV-EF1α-EGFP-hyg-lox). The constitutive EF1α promoter was used to facilitate 
transgene expression in both cell lines. 
 
4.2.1 Generation of Transgenic HeLa Cells  
Following transduction with BV-EF1α-EGFP-hyg-lox at a MOI of 10, 50 or 100 (co-
transduction with BV-EF1α-Cre remained constant at a MOI of 100) the numbers of 
colonies propagated through hygromycin B selection were two, twenty-eight and 
forty-one respectively. These colonies were expanded and their DNA was subjected 
to PCR genotyping by using a primer specific for chromosome 19 and a primer 
specific for the EF1α promoter present in the baculoviral vector containing the EF1α-
EGFP-hyg-lox cassette (Figure 4.4). The amplification of a 4.2 kb fragment 
confirmed the integration of the EGFP gene within the AAVS1 by RMCE. From this 
analysis, when transduced at a MOI of 10, 50 or 100 the numbers of clones identified 
as having undergone site-specific integration was one, twenty-one and twenty-three 
respectively (Figure 4.5, Table 4.3).  
Transduction of loxP-HeLa45 cells with only BV-EF1α-EGFP-hyg-lox (no Cre 
expression) at a MOI of 100 yielded seventeen EGFP-HeLa colonies through 
hygromycin B selection. This result is consistent with previous reports which reveal 
the ability of baculovirus to stably transduce in HeLa cells [88]. EGFP-HeLa Clone #1 
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(EGFP-HeLa50-1) which was generated by transducing loxP-HeLa45 cells at a MOI 
of 50 was randomly selected and subjected to further analysis. 
  
4.2.2 Generation of Transgenic hESCs 
Following three independent transduction experiments, a total of thirty-three EGFP-
hESC colonies propagated through hygromycin B selection. These colonies were 
expanded and their DNA was subjected to PCR genotyping by using a primer 
specific for chromosome 19 and a primer specific for the EF1α promoter present in 
the baculoviral vector containing the EF1α-EGFP-hyg-lox cassette (Figure 4.4). The 
amplification of a 4.2 kb fragment confirmed the integration of the EGFP gene within 
the AAVS1 by RMCE. From this analysis, thirty EGFP-hESC clones were identified 
as having undergone site-specific integration (Figure 4.6A, Table 4.4).  
Transduction of wild-type hESCs with BV-EF1α-Cre and BV-EF1α-EGFP-hyg-lox and 
transduction of loxP-hESC2 with only BV-EF1α-EGFP-hyg-lox yielded no colonies 
through hygromycin B selection. These results suggest that loxP sites within the 
genome and the expression of Cre recombinase are both necessary for BV-RMCE. It 
also suggests that unlike HeLa cells, hESCs are not readily stably transduced by 
baculovirus.     
To dismiss the possible existence of multiple transgene copies within the clones, 
using a probe specific for the EGFP gene Southern blot analysis was performed on 
all the EGFP-hESC clones. The detection of a 3.8 kb fragment confirmed the 
integration of the EGFP gene within AAVS1 and the inability to detect fragments of 
other sizes confirmed the absence of random integration (Figure 4.4).  This analysis 
revealed that all thirty EGFP-hESC clones that were identified by PCR genotyping as 
having undergone site-specific integration contained only one EGFP gene copy 
(Figure 4.6B). The EGFP-hESC clones that lack amplification of the 4.2 kb fragment 
by PCR genotyping (Clones #3, #12 and #17) also contained one EGFP gene copy 
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as revealed by Southern blot analysis, but fragments clearly differing from 3.8 kb in 
length were detected thereby identifying the three clones as having undergone 
random integration. EGFP-hESC Clone #1 (EGFP-hESC1) was randomly selected 



























































Figure 4.4: Schematic representation for detection of BV-RMCE. Detection of EGFP 
integration within the AAVS1 by PCR genotyping following cassette exchange in the 
presence of Cre recombinase and verification of EGFP copy number and site-specific 
integration by Southern blot analysis. (AA.., ..VS1 depict a disrupted AAVS1)   

























Figure 4.5: Detection of RMCE in HeLa cells. EGFP-HeLa clones that underwent 
site-specific integration were identified by PCR genotyping through amplification of a 

















Table 4.3: Efficiencies of EGFP integration within the AAVS1 in HeLa 
cells by BV-RMCE 
 MOI 10 MOI 50 MOI 100 
No. of transduced cells 50,000 50,000 50,000 
No. of hygromycin B resistant colonies 2 28 41 
No. of correctly recombined clones identified by 
PCR genotyping 
1 21 23 
Site-specific integration efficiency (%) 50.00 75.00 56.09 
























Figure 4.6: Detection of RMCE in hESCs. (A) PCR genotyping for detection of EGFP 
integration within the AAVS1. EGFP-hESC clones that underwent site-specific 
integration were identified through amplification of a 4.2 kb fragment. (B) Southern 
blot analysis to verify RMCE and transgene copy number. Following digestion with 
NcoI and hybridization, a solitary fragment (3.8 kb) was detected in all EGFP-hESC 
clones that underwent site-specific integration. A fragment of dissimilar size was 
detected in EGFP-hESC clones (Clones #3, #12 and #17) which underwent random 
integration.  





Table 4.4: Efficiencies of EGFP integration within the AAVS1 in hESCs 
by BV-RMCE 
 Exp 1 Exp 2 Exp 3 
No. of transduced cells 2,000,000 2,000,000 2,000,000 
No. of hygromycin B resistant colonies 9 18 6 
No. of correctly targeted clones identified by 
PCR genotyping 
8 16 6 
No. of correctly targeted clones verified by 
Southern blot analysis 
8 16 6 
Site-specific integration efficiency (%) 88.89 88.89 100 
Mean site-specific integration efficiency (%) ± 
SD 
92.59 ± 6.41 























4.3 AAVS1-Directed Transgene Integration Results in Persistent 
Expression 
In an attempt to understand whether the AAVS1 is indeed resistant to epigenetic 
silencing phenomena and if transgene integration within this locus does in fact result 
in persistent expression, the EGFP-cell lines (EGFP-HeLa50-1 and EGFP-hESC1) 
were expanded in the absence of drug selection. 
 
4.3.1 Expression Analysis in Transgenic HeLa Cells 
Relative to the MOI, EGFP expression was still visible in HeLa cells 48 hours 
following baculovirus transduction (Figure 4.7A, a-c). Once selection was initiated 
most of the cells had been eliminated within the first week, but after 2 weeks 
hygromycin B resistant EGFP-HeLa colonies emerged (Figure 4.7A, d). These 
colonies were isolated and cultured in selection medium for an additional 2 weeks, 
thereby amounting to a total of 4 weeks of selection. Flow cytometric analysis 
revealed that 99.73% of EGFP-HeLa50-1 cells expressed the transgene at a 
constant intensity (Figure 4.7B). Selection medium was then withdrawn and these 
cells were cultured for a further 8 weeks over 24 passages (12 weeks post co-
transduction). Flow cytometric analysis revealed that the EGFP gene continued to 
maintain persistent expression at the same intensity as before ceasing drug 
selection.  
 
4.3.2 Expression Analysis in Transgenic hESCs 
EGFP expression was still visible in hESCs 48 hours following baculoviral 
transduction (Figure 4.8A, a). Once selection was initiated most of the cells had 
been eliminated within the first week, but after 2 weeks hygromycin B resistant 
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EGFP-hESC colonies emerged (Figure 4.8A, b). Since these colonies were much 
smaller than the EGFP-HeLa colonies they were not isolated but maintained for an 
additional 2 weeks in selection medium, thereby amounting to a total of 4 weeks of 
selection (Figure 4.8A, c). Three weeks following the cessation of drug selection, 
flow cytometric analysis revealed that 99.82% of EGFP-hESC1 expressed the 
transgene at a constant intensity (Figure 4.8B). These cells were then cultured for a 
further 20 weeks over 20 passages (27 weeks post transduction) and flow cytometric 
analysis revealed that the EGFP gene continued to maintain persistent expression at 
the same intensity as before. 
Two EGFP-hESC clones that underwent random integration (Clones #3 and #12) 
were also studied. Both EGFP-hESC3 and EGFP-hESC12 populations were 
obtained following 4 weeks of hygromycin B selection. However, 7 weeks following 
the cessation of drug selection, flow cytometric analysis revealed a decline in the 
intensities corresponding to EGFP expression in both populations (Figure 4.8C). It 
also revealed that the EGFP gene had been silenced in 30% of EGFP-hESC12 and 
35% of EGFP-hESC3. These results are consistent with previous reports which 
demonstrate that random integration is subjected to epigenetic silencing phenomena 
[42-44]. It also confirms that transgene integration within the AAVS1 does in fact 

















Figure 4.7: Persistent transgene expression in EGFP-HeLa cells. (A) EGFP 
expression as demonstrated with fluorescence imaging. Cells were photographed 48 
hours post transduction (a-c) and 2 weeks following drug selection (d). (B) EGFP 
expression in EGFP-HeLa50-1. Cells were photographed and transgene expression 
was quantified by flow cytometric analysis 4 weeks following drug selection and 8 








Figure 4.8: Persistent transgene expression in EGFP-hESCs. (A) EGFP expression 
as demonstrated with fluorescence imaging. Cells were photographed 48 hours post 
transduction (a) and 2 and 3 weeks following drug selection (b-c). (B) EGFP 
expression in EGFP-hESC1. Cells were photographed and transgene expression 
was quantified by flow cytometric analysis 3 and 20 weeks following the cessation of 
drug selection. (C) EGFP expression in EGFP-hESC3 and EGFP-hESC12. Cells 
were photographed and transgene expression was quantified by flow cytometric 
analysis 7 weeks following the cessation of drug selection.  
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4.4 AAVS1-Directed Transgene Integration Does Not Affect hESC 
Pluripotency  
Having undergone a 2-step genetic modification process (plasmid transfection and 
baculovirus transduction) and also having been subjected to a biphasic selection 
strategy (G418 and hygromycin B) it was necessary to ensure that the EGFP-hESCs 
had maintained their “stemness” property. Hence, these cells were analyzed for 
pluripotent markers.  
 
4.4.1 Phenotype Comparison of Genetically Modified hESCs 
Surface antigens such as SSEA-4, Tra-1-60 and Tra-1-81 are human pluripotent 
stem cell markers. To ensure that the hESC phenotype had not undergone any such 
change following each step of genetic modification and drug selection, we compared 
the existence of these markers between wild-type hESCs, loxP-hESC2 and EGFP-
hESC1. When compared with wild-type hESCs, both loxP-hESC2 and EGFP-hESC1 
expressed these markers (Figure 4.9) thus confirming that neither plasmid 
transfection followed by G418 selection (loxP-hESC2) nor baculoviral transduction 
followed by hygromycin B selection (EGFP-hESC1) had any significant effect in 
altering the hESC phenotype. Furthermore both genetically modified cell lines 
displayed colony morphology when viewed under bright-field and fluorescence. This 
morphology is consistent with that of wild-type hESCs. 
  
4.4.2 Confirmation of Pluripotency in Transgenic hESCs 
Oct-3/4, SOX2 and Nanog are pluripotent markers. Hence, EGFP-hESC1 were 
analyzed for the expression of these markers for which they were positive as 
revealed by immunostaining (Figure 4.10A). Further analysis by RT-PCR revealed 
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that whilst EGFP-hESC1 expressed pluripotent markers such as Oct-3/4 and Nanog, 
they did not express stem cell lineage markers (Figure 4.10C).           
Embryoid bodies were then derived from EGFP-hESC1. These embryoid bodies 
displayed no loss of EGFP expression (Figure 4.10B). EGFP-embryoid bodies were 
also analyzed for the expression of pluripotent markers for which they were negative 
as revealed by RT-PCR. However, they expressed ectoderm (Pax6, NeuroD), 
mesoderm (Brachyury) and endoderm (AFP) markers (Figure 4.10C). These results 
confirmed that transgene integration within the AAVS1 did not affect hESC 

























Figure 4.9: Detection of hESC surface antigens. Wild-type hESCs, loxP-hESC2 and 
EGFP-hESC1 were subjected to immunostaining for detection of SSEA-4, Tra-1-60 





Figure 4.10: Confirmation of EGFP-hESC pluripotency. (A) Immunostaining for 
detecting expression of pluripotent markers Oct-3/4, Sox2, Nanog and SSEA-4 in 
EGFP-hESC1. (B) EGFP-hESC1-derived embryoid body. (C) RT-PCR analysis for 
detecting expression of pluripotent markers and stem cell lineage markers in EGFP-
hESC1 and derived embryoid bodies. Note that EGFP-hESC1 expresses pluripotent 
markers Oct-3/4 and Nanog while EGFP-embryoid bodies express ectoderm markers 
Pax6 and NeuroD, mesoderm marker Brachyury and endoderm marker AFP. 
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4.5 Persistent Transgene Expression Maintained Following hESC 
Differentiation 
Having confirmed that EGFP-hESCs retained their phenotype and pluripotency 
following genetic modification, they were then differentiated into various cell lineages 
to verify whether transgene integration within the AAVS1 would still result in 
persistent expression upon hESC differentiation. 
  
4.5.1 Transgenic Neural Stem Cell Derivation and Terminal 
Differentiation  
Through the derivation of neurospheres, EGFP-hESC1 were differentiated into neural 
stem cells (NSCs). Neurospheres derived from EGFP-hESC1 were cultured for 4 
weeks and displayed no loss of EGFP expression (Figure 4.11A). SOX2, SOX1, and 
Pax6 are neuro-progenitor cell markers. To ensure that EGFP-NSCs are indeed of 
neaural lineage, we compared the existence of these markers between EGFP-
hESC1, EGFP-NSCs and wild-type NSCs (derived from wild-type hESCs). All three 
cell types expressed these markers with both EGFP-NSCs and wild-type NSCs 
displaying an up-regulation of SOX1 and Pax6 as revealed by RT-PCR analysis 
(Figure 4.11B). 
Prior to their terminal differentiation, EGFP-neursospheres were seeded as adherent 
cells. These cells were then analyzed for the expression of the primary neural lineage 
marker Nestin for which they were positive as revealed by immunostaining (Figure 
4.11C). EGFP-NSCs were then terminally differentiated into gial cells which 
expressed GFAP and neurons which expressed β-III Tubulin Figure 4.11D, E). 




4.5.2 Transgenic Mesenchymal Stem Cell Derivation 
Through the derivation of embryoid bodies, EGFP-hESC1 were differentiated into 
mesenchymal stem cells (MSCs). Following the seeding of EGFP-embryoid bodies, 
cells displaying fibroblast morphology were visible 7 days later (Figure 4.12A). Once 
harvested, these cells were cultured for 2 weeks and displayed no loss of EGFP 
expression with flow cytometric analysis revealing that ~ 92% of the cells expressed 
the transgene at a constant intensity (Figure 4.12B). CD44, CD73, CD90, CD105 
and CD166 are MSC markers. To ensure that EGFP-MSCs are indeed of 
mesenchumal lineage, cells were analyzed for the expression of these markers for 
which they were positive as revealed by flow cytometry (Figure 4.12C). 
Since haematopoietic progenitor cells (HPCs) are also derived from mesodermal 
lineage, it was necessary to ensure that such cells had not been derived from EGFP-
embryoid bodies together with EGFP-MSCs. CD24, CD34 and CD45 are HPC 
markers. EGFP-MSCs were analyzed for the expression of these markers for which 
they were negative as revealed by flow cytometry (Figure 4.12C).   
EGFP-MSCs also expressed HLA-ABC, a marker found in all nucleated cells but did 
not express HLA-D(RQP), a marker found only in antigen-presenting cells. 
   
4.5.3 Transgenic Dendritic Cell Derivation 
Through co-culture with OP9 cells, EGFP-hESC1 were differentiated into dendritic 
cells (DCs). Following their seeding on a layer of OP9 cells, cells displaying 
hemangioblast morphology were visible within the EGFP-hESC colonies 9 days later 
(Figure 4.13A). Once harvested these cells were terminally differentiated into DCs 
and cultured for 2 weeks. EGFP-DCs displayed no loss of EGFP expression with flow 
cytometric analysis revealing that ~ 98% of the cells expressed the transgene at a 
constant intensity (Figure 4.13B). CD86, CD40, CD11c, and CD209 are DC markers. 
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To ensure that EGFP-DCs are indeed of haematopoietic lineage, cells were analyzed 
for the expression of these markers for which they were positive as revealed by flow 
cytometry (Figure 4.13C). It also revealed that EGFP-DCs expressed CD45, the 
primary marker characteristic of haematopoietic lineage. 
The maintenance of EGFP expression following the differentiation of EGFP-hESC 
into ectoderm (NSCs, glial cells, neurons) and mesoderm (MSCs, DCs) lineages 
confirmed that transgene integration within the AAVS1 results in persistent 





Figure 4.11: Derivation, characterization and terminal differentiation of EGFP-NSCs. 
(A) EGFP-hESC1-derived neurospheres. Cells were photographed 4 weeks following 
their derivation. (B) Molecular characterization of ectoderm-derived cells. 
Neurospheres derived from EGFP-hESC1 and wild-type hESCs were analyzed by 
RT-PCR. Neurospheres derived from both hESC lines expressed SOX2 as well as 
displayed an up-regulation of neural progenitor marker SOX1 and Pax6 when 
compared with EGFP-hESC1. (C) Nestin-positive EGFP-NSCs prior to their terminal 
differentiation. (D-E) Terminal differentiation of EGFP-NSCs. Glial cells were 




Figure 4.12: Derivation and characterization of EGFP-MSCs. (A) Emerging EGFP-
MSCs following the seeding of EGFP-embryoid bodies. (B) EGFP expression in 
EGFP-hESC1-derived MSCs. Cells were photographed and transgene expression 
was quantified by flow cytometric analysis 2 weeks following their derivation. (C) 
Flow cytometric characterization of mesoderm-derived cells. EGFP-MSCs expressed 
all five MSC markers CD44, CD73, CD90, CD105 and CD166 as well as HLA-ABC 









Figure 4.13: Derivation and characterization of EGFP-DCs. (A) EGFP-hESC and 
OP9 cell co-culture. Arrows indicate hemangioblasts. (B) EGFP expression in EGFP-
hESC1-derived DCs. Cells were photographed and transgene expression was 
quantified by flow cytometric analysis 2 weeks following their derivation. (C) Flow 
cytometric characterization of dendritic cells. EGFP-DCs expressed DC markers 






4.6 Glioma Gene Therapy Potential of BV-RMCE 
The herpes simplex virus thymidine kinase (HSVtk)/GCV system is a commonly 
utilised cancer gene therapy regime. Although harmless on its own, in the presence 
of HSVtk, GCV undergoes phosphorylation, enabling its incorporation into the 
genome and thus inhibiting DNA replication [99]. Phosphorylated-GCV molecules 
may further display a bystander killing effect by diffusing into nearby tumor cells. 
Hence, to demonstrate the clinical potential of BV-RMCE, we generated a hESC line 
expressing the HSVtk suicide gene from the master loxP-hESC2 line.  
 
4.6.1 Generation of Transgenic hESCs 
Following transduction with BV-EF1α-Cre and BV-EF1α-HSVtk-hyg-lox, four colonies 
propagated through hygromycin B selection. These colonies were expanded and 
their DNA was subjected to PCR genotyping by using a primer specific for 
chromosome 19 and a primer specific for the HSVtk gene present in the baculoviral 
vector containing the EF1α-HSVtk-hyg-lox cassette (Figure 4.14A). The amplification 
of a 3.5 kb fragment confirmed the integration of the HSVtk suicide gene within the 
AAVS1 by RMCE. From this analysis, all four clones were identified as having 
undergone site-specific integration (Figure 4.14B, Table 4.5). TK-hESC Clone #1 
(TK-hESC1) was randomly selected and subjected to neural differentiation for cancer 
therapy studies. Further analysis by RT-PCR revealed that whilst both TK-hESC1 
and TK-NSCs expressed HSVtk, wild-type NSCs did not express the suicide gene 
(Figure 4.14C). 
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4.6.2 Gap Junction-Mediated Bystander Killing Effect of Transgenic 
NSCs 
By co-culture of TK-NSCs with U87 human glioma cells at a 1:1 ratio, this experiment 
attempted to study their ability to kill cancer cells through bystander killing effects. 
One week following the addition of GCV, wild-type NSCs transiently transduced with 
BV-EF1α-HSVtk-hyg-lox (BV-TK) had killed 55.93 ± 4.51% of the co-culture. TK-
NSCs however, had killed 86.74 ± 4.64% of the co-culture (Figure 4.15A, B). The 
enhanced killing effect displayed by TK-NSCs was attributed to the persistent 
expression of HSVtk as a result of its integration within the AAVS1 as opposed to its 
transient expression found in wild-type NSCs transduced with baculovirus. 
        
4.6.3 Tumor Migratory Properties of Transgenic NSCs 
NSCs have been found to migrate towards tumors and can therefore be used in a 
Trojan horse approach as cellular vehicles for the targeted delivery of therapeutic 
genes to distant tumor sites [100, 101]. Boyden chambers were used to study the 
tumor tropism of calcein-labelled TK-NSCs (Figure 4.16A). Approximately 70% of 
TK-NSCs displayed the ability to migrate towards U87 cells as opposed to ~ 30% 
that migrated towards plain Opti-MEM cell culture medium (Figure 4.16B).  
The enhanced tumor killing effect and strong tumor tropism displayed by TK-NSCs 
confirms that these cells are functionally adequate for the targeting of tumors 











Figure 4.14: Detection of RMCE (HSVtk) in hESCs and transgene expression 
analysis in derived cells. (A) Schematic representation for detection of HSVtk 
integration within the AAVS1 by PCR genotyping following cassette exchange in the 
presence of Cre recombinase. (AA.., ..VS1 depict a disrupted AAVS1) (B) PCR 
genotyping for detection of HSVtk integration within the AAVS1. TK-hESC clones that 
underwent site-specific integration were identified through amplification of a 3.5 kb 
fragment. (C) RT-PCR analysis for detection of HSVtk expression in TK-hESC1 and 




Table 4.5: Efficiency of HSVtk integration within the AAVS1 in hESCs by 
BV-RMCE 
No. of transduced cells 2,000,000 
No. of hygromycin B resistant colonies 4 
No. of correctly targeted clones identified by PCR genotyping 4 
Site-specific integration efficiency (%) 100 




























Figure 4.15: Tumor killing effect of TK-NSCs. (A) NSC and U87 cell co-culture in the 
presence of GCV. Note the significant decline in cell viability when TK-NSCs are co-
cultured with U87 cells. (B) Cell viability analysis following in vitro tumor killing. Each 
group consisted of ten repeats and values are expressed as mean ± SD. *P < 0.05 











Figure 4.16: Tumor tropism of TK-NSCs. (A) Schematic representation of a Boyden 
chamber. Photographs of calcein-labelled TK-NSCs and U87 cells are taken prior to 
their seeding in the inserts and receiver plates respectively. (B) Migration of TK-
NSCs towards U87 glioma cells. Each group consisted of seven repeats and values 
are expressed as mean ± SD. *P < 0.05 vs. the migration towards Opti-MEM by an 




4.7 Zinc-Finger Nuclease-Mediated Homologous Recombination at 
the AAVS1 Using Baculoviral Vectors 
Having developed a successful technique for generating transgenic hESC lines, we 
began to ponder as to what limitations might be associated with this approach. BV-
RMCE is heavily dependent on the initial step of homologous recombination which 
introduces heterospecific loxP sites into the AAVS1. It also relies on a biphasic 
selection strategy which allows for the screening of correctly genetically modified 
clones. Since plasmid transfection was used to mediate homologous recombination 
(conventional), this was foreseen as a potential limitation, as studies have shown the 
inefficiency of this method [65].  Also, cellular stress caused by two rounds of drug 
selection (biphasic) may lead to complications in the long run. Therefore, the ability of 
a baculovirus-zinc-finger nuclease (BV-ZFN) system to mediate homologous 
recombination as well as induce persistent transgene expression in the absence of 
drug selection was assessed. 
HeLa cells were subjected to BV-ZFN technology and for this purpose two 
baculoviral vectors were generated, one to express both left and right ZFNs (BV-
EF1α-ZFN-IRES) and the other the transgene donor (BV-EF1α-EGFP-AAVS1). The 
constitutive EF1α promoter was used to facilitate transgene expression. To target the 
AAVS1 on chromosome 19 (19q13.42), the transgene donor contained an EGFP 
gene flanked by a left and right arm corresponding to ~ 1.6 kb of homology of the 
PPP1R12C gene. Unlike pBS-PGK-neo-lox, none of the exons were present in these 
arms although the region targeted was the same as before; intron 1 (19:60318931 – 
19:60318961). 





4.7.1 Genetic Modification in the Absence of Drug Selection 
Seventy-two hours following transduction with BV-EF1α-EGFP-AAVS1 or co-
transduction transduction with BV-EF1α-EGFP-AAVS1 and BV-EF1α-ZFN-IRES, the 
DNA of each cell population was subjected to PCR genotyping by using a primer 
specific for the EGFP gene present in the transgene donor baculoviral vector and a 
primer specific for chromosome 19 downstream of the 3` end of the right homologous 
arm (Figure 4.17A). The amplification of a 1.8 kb fragment confirmed the successful 
integration of the transgene within the AAVS1 by homologous recombination. From 
this analysis, the cell population that had been co-transduced was identified as 
containing a modified AAVS1 (Figure 4.17B).   
 
4.7.2 Transgene Expression Analysis 
Forty-eight hours following transduction or co-transduction, ~ 75% of the cells in each 
population expressed the transgene as revealed by flow cytometric analysis (Figure 
4.18A). A week later, both cell populations displayed a dramatic loss of transgene 
expression with EGFP-cells decreasing to ~ 6%. Cells that had been co-transduced 
however contained a distinct sub-population (~ 1%) that expressed EGFP at a high 
intensity. Such a population was not present within the cells transduced with only BV-
EF1α-EGFP-AAVS1. Two weeks later both transduced and co-transduced cells 
displayed almost a total absence of transgene expression except for the EGFP-sub-
population that was still present within the latter population (Figure 4.18A, B).  
Apart from demonstrating the transient transduction ability of baculovirus, these 
results also suggest that both transgene donor and respective ZFNs are necessary 















Figure 4.17: Detection of ZFN-mediated homologous recombination in HeLa cells. 
(A) Schematic representation for detection of a modified AAVS1 by PCR genotyping 
following its targeting with BV-EF1α-EGFP-AAVS1 in the presence of ZFNs. (AA.., 
..VS1 depict a disrupted AAVS1) (B) PCR genotyping for detection of a modified 
AAVS1. Cell populations that underwent homologous recombination were identified 













Figure 4.18: ZFN-induced persistent transgene expression in HeLa cells. (A) EGFP 
expression in transduced and co-transduced cell populations. Transgene expression 
was quantified by flow cytometric analysis 48 hours, 1 week and 2 weeks post 
transduction. Highlighted sub-population indicates cells that display persistent 
transgene expression. (B) EGFP expression as demonstrated with fluorescence 




5.1 Gene Targeting by Homologous Recombination 
Over the years, homologous recombination has been an effective tool in gene 
targeting studies. Particularly in the mouse model, where genes of interest are 
targeted in mouse embryonic stem cells (mESCs) and then injected into the 
blastocyst from which transgenic animals containing the targeted genes are 
generated [102-104]. Human cell lines have also been subjected to gene targeting, 
with the β-globin gene being the first to be targeted by homologous recombination 
[105]. Since then, various genes have been targeted in human cancer cell lines and 
primary cell lines [106-117]. More recently gene targeting in human embryonic stem 
cells (hESCs) has also been achieved [12, 118-123].  
Apart from the various selection strategies such as simple positive selection, positive-
negative selection, promoter-trap positive selection and polyadenylation-trap positive 
selection, the targeting of a gene by homologous recombination can be achieved in 
numerous ways. The most common approach (conventional homologous 
recombination) uses a linearized plasmid containing isogenic DNA homologous to 
the chromosomal region intended to be targeted [118]. The use of non-isogenic DNA 
has also shown to be successful in gene targeting [12, 120]. However, when utilising 
this approach the recombination frequency is low, usually occurring in one out of a 
million treated cells [65]. Newer methods for gene targeting include the use of 
previously discussed ZFNs, TALENs and adenoviral vectors [65-67, 71, 124, 125]. 
Through the use of ZFN-mediated and TALEN-mediated homologous recombination, 
the targeting efficiency at a locus, for instance the AAVS1 is greatly enhanced [66, 
71]. However, the efficiency of the former system is dependent on the type of ZFN 
pair used as demonstrated with the targeting of the POU5F1 locus [66]. Also, the 
induction of off-target DNA breaks at related sequences throughout the genome 
could lead to potentially hazardous effects [67]. Due to the large size of each amino 
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acid repeat unit, complications could arise during the synthesis and delivery of 
TALENs [69].   
Prior to this study, there have been no reports regarding the targeting of the AAVS1 
by conventional homologous recombination in either differentiated cells or stem cells. 
  
5.1.1 Cell Type Influences Recombination Frequency  
When introducing a floxed neomycin resistance gene into the AAVS1 in HeLa cells, a 
recombination frequency of 9 x 10-5 was achieved with a targeting efficiency of 36% 
(Table 4.1). Furthermore, the generation of fifty-plus colonies from a single 
transfection experiment suggests that these cells have a high clonal efficiency. On 
the other hand, gene targeting by homologous recombination is difficult to achieve in 
hESCs, primarily due to low clonal efficiency and low gene transfer efficiency [126]. 
So far, only several genes, including POU5F1, HPRT1, ROSA26, Fezf2 and Olig2, 
have been successfully targeted by conventional homologous recombination, with 
varying targeting efficiencies ranging from as low as 1.5% to as high as 40% [12, 
118-123]. When targeting the AAVS1 in hESCs with the targeting construct pBS-
PGK-neo-lox, a recombination frequency of 2 x 10-6 was achieved with a targeting 
efficiency of 30.56 ± 12.11% (Table 4.2). Furthermore, the average number of 
colonies generated from three independent transfection experiments was thirteen 
which is significantly less than what was generated when transfecting HeLa cells, 
thus further confirming the poor clonal efficiency and gene transfer efficiency of 
hESCs. 
Although the AAVS1 targeting efficiencies are similar for both cells lines (30% and 
36%), the recombination frequency in HeLa cells is 45-folds higher than in hESCs. 
This could be attributed to the high gene transfer efficiency in HeLa cells. However, 
to truly understand the reasons for these disparate recombination frequencies we 
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perhaps need to take a closer look at the proteins involved in this mechanism. 
Studies have revealed that whilst the over-expression of RAD51 increases the gene 
targeting frequency in HT1080 cells (human fibrosarcoma) the loss of RAD54B 
decreases the frequency in HCT116 cells (human colon carcinoma) [127, 128]. Both 
these proteins are involved in DNA repair and recombination pathways and may be 
expressed differentially depending on the type of cell being targeted. It has been 
reported that certain tumors including cervical carcinomas (the origin of HeLa cells) 
over-express RAD51 which leads to genomic instability [129, 130]. Hence, we 
speculate that this may account for the varying recombination frequencies observed 
between the two cell lines. Previously, the targeting of the 6-16 gene in HeLa cells at 
a frequency of 6 x 10-4 suggests that homologous recombination can even occur at 
higher frequencies than what was achieved [112].  
 
5.1.2 Targeting Construct Influences Recombination Frequency  
When using the longer targeting construct, pBS-EF1α-EGFP-neo-lox which contains 
identical homologous arms, for integration of the EGFP gene and the neomycin 
resistance gene simultaneously within the AAVS1 through homologous 
recombination in hESCs, the targeting efficiency and recombination frequency 
decreased by > 3-folds and 4-folds respectively (Table 4.2). This result suggests that 
apart from the homologous arms, targeting efficiency and frequency is also 
influenced by the sequence of the integrated gene and its regulatory elements 
present in the targeting construct. Hence, it is likely that the integration of a large 
transgene together with a cellular promoter within the AAVS1 by homologous 
recombination would be a challenging task, even when the homologous arms are 
available. This issue perhaps could be resolved if longer homologous arms were 
used as studies in mESCs have revealed that the recombination frequency when 
targeting the HPRT locus is dependent on the extent of homology between the 
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exogenous and endogenous sequences [104]. However, contradictory to this, it has 
also been revealed that when targeting the β-globin locus, long homologous arms 
had no effect on the recombination frequency [131]. 
In this study, we demonstrated for the first time the targeting of the AAVS1 in human 
cells by conventional homologous recombination and without the induction of DNA 
double-strand breaks. From this discussion we also infer that gene targeting by 
conventional homologous recombination is unpredictable as the recombination 
frequency is dependent on multiple parameters such as the cell type, the targeted 
















5.2 Cre/loxP Recombinase System – A Versatile Tool for Genome 
Modification 
The bacteriophage P1-derived Cre/loxP system has proved to be an effective tool for 
the genetic modification of mammalian cells and transgenic animals owing to the high 
activity of Cre recombinase together with its high degree of DNA sequence specificity 
[82-86]. This 38 kDa recombinase protein recognises and binds to specific DNA 
sequences known as loxP sites where it catalyses both intra-molecular (excision and 
inversion) and inter-molecular (integration and translocation) recombination [82]. The 
loxP site which is 34 bp in length contains an 8 bp central spacer element (CSE) 
which determines its orientation and thus the type of recombination that takes place. 
For instance two loxP sites in the same orientation would result in an excision event 
whereas in the opposite orientation would result in an inversion event. The CSE is 
flanked by two 13 bp inverted repeats, each containing a Cre-binding domain. Upon 
covalently binding to these domains, the recombinase nicks and produces a 6 bp 
staggered cut within the CSE which takes part in strand exchange during the 
recombination event [132].  
 
5.2.1 Mutated loxP Sites Enhance Site-Specific Transgene Integration 
Efficiency 
Once loxP sites are introduced into a pre-defined locus in the host cell genome by 
homologous recombination, the recombinase can then catalyse the integration of a 
floxed transgene (flanked by loxP sites) within the selected site. Since the loxP sites 
flanking the transgene still exist and remain unmodified following recombination, in 
the presence of Cre the integration event is soon followed by an excision event 
between these two similar sites as it is thermodynamically more favourable [133]. 
Whilst this property makes the Cre/loxP system a versatile tool for understanding 
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biological events caused by gene knockdown and gene activation in transgenic 
animals, it hinders its use in therapeutic applications where permanent transgene 
integration is required [85, 134]. One way in which to overcome this issue is by using 
mutated half loxP sites which eliminate the intra-molecular excision event, but at the 
cost of a reduced integration efficiency [84]. Another approach that has proven its 
success is RMCE, where the principle concept surrounding it is that recombination 
does not take place between two dissimilar loxP sites (wild-type and mutant) but 
does so between two similar sites (mutant and mutant or wild-type and wild-type). 
Hence, in this approach Cre exchanges a genomic fragment flanked by 
heterospecific loxP sites for a floxed transgene flanked by the same heterospecific 
loxP sites. Once cassette exchange takes place, the loxP sites flanking the 
transgene are still incompatible and hence the ability for the recombinase to catalyse 
an excision event between these two dissimilar sites is significantly diminished 
thereby enabling unidirectional integration. The commonly used mutated loxP site in 
RMCE is lox511. However, as it contains only a single point mutation Cre is still able 
to catalyse an excision event, albeit at a lower frequency [135]. Hence, for this study 
we chose to use lox2722, a loxP site which contains two point mutations thereby 
averting the excision event. The use of the lox2722 site in RMCE has achieved 
significantly high integration efficiencies in mESCs [136]. RMCE has also been 
performed in hESCs at random genomic sites as well as in pre-defined sites such as 
the ROSA26 and HPRT loci [119, 120, 123, 137, 138]. Furthermore, as 
demonstrated in differentiated somatic cells, viral transduction is significantly more 
effective in mediating RMCE than plasmid transfection [139].  
 
5.2.2 MOI of Transgene Donor Influences RMCE Efficiency in HeLa Cells 
Apart from targeting the AAVS1 by homologous recombination, we also attempted to 
integrate the EGFP gene within this locus through RMCE. The efficiency of RMCE is 
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dependent on the relative and absolute quantities of transgene DNA and 
recombinase present in a cell. When transduced at a low MOI of 10, HeLa cells 
underwent RMCE at an efficiency of 50% which could be attributed to the very low 
copy numbers of the transgene donor within the cells. Therefore, transduction at a 
higher MOI would result in more copies of the transgene donor which in turn would 
increase the number of target sites for Cre and thus enhance the opportunity for 
RMCE. However, whilst the RMCE efficiency was significantly increased to 75% 
when cells were transduced at a MOI of 50, a decline of ~ 20% was seen at a MOI of 
100 (Table 4.3). Therefore, we speculate that whilst an increase of the transgene 
donor copy number may enhance the opportunity for RMCE, too much of an increase 
would result in random integration. Baculoviral vectors are capable of stably 
transducing HeLa cells and as discussed previously, the differential expression of 
DNA repair and recombination proteins may enable HeLa cells to integrate an extra-
chromosomal DNA fragment more readily into the genome thereby resulting in 
random integration [88, 129, 130]. The observation of a direct correlation between 
the number of colonies generated and the MOI of the transgene donor further 
strengthens our theory. 
 
5.2.3 Baculovirus Transduction Mediates Efficient RMCE in hESCs 
The Cre/loxP system has been utilized in attaining genetic modifications in hESCs 
[119, 120, 123, 137, 138]. For example, through the use of a cell-permeable Cre 
recombinase a highly efficient site-specific recombination frequency has been 
achieved in these cells [137]. However, apart from demonstrating the recombination 
inducing ability of Cre to excise an integrated cassette, this study did not utilise 
RMCE to integrate transgenes into a specifically defined locus. Furthermore, 
following the screening of transgene silencing-resistant hESC lines that contain one 
integrated copy of a built-in loxP exchange cassette, a cell permeable Cre 
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recombinase was used for site-specific gene integration through RMCE [138]. As 
revealed in this study, a RMCE efficiency of ~ 33% was achieved with the rest of the 
clones having undergone random integration.  
The Cre/loxP system has been combined with the use of adenoviral vectors to 
successfully induce RMCE in somatic cells [139]. However, a major drawback with 
the adenovirus system was that RMCE was only successful in cells that supported 
adenoviral replication since high copy numbers of the viral vectors were required 
within the cells. Obviously, any sort of viral replication within transplantable cells is 
precarious and hence the use of this system in the clinical setting is undesirable. On 
the other hand, due to the high transduction efficiency of our baculoviral vectors in 
hESCs, the integration of the EGFP gene and the HSVtk suicide gene within the 
AAVS1 through BV-RMCE resulted in site-specific targeting efficiencies of 92.59 ± 
6.42% and 100% respectively (Table 4.4, 4.5). This result also confirmed that unlike 
in HeLa cells baculoviral vectors have limited random integration ability in hESCs. 
By generating a loxP-hESC line through conventional homologous recombination 
and by developing the BV-RMCE technique, we have provided a safer alternative for 









5.3 Therapeutic Gene Delivery by Baculoviral Vectors 
The baculovirus Autographa californica multiple nuclear polyhedrosis virus 
(AcMNPV) is a large, rod-shaped insect virus which contains a circular 134 kb 
double-stranded DNA genome. Although primarily used as a eukaryotic protein 
production system in insect cell lines, vectors derived from this virus have 
tremendous therapeutic potential.  
 
5.3.1 Baculoviral Vectors Mediate Efficient Gene Delivery in hESCs 
The use of baculoviral vectors for the delivery of Cre recombinase and the floxed 
transgene in this study is justified by several factors. Previously, the use of lentiviral 
vectors was shown to achieve high transient transduction efficiencies as well as 
induce persistent transgene expression in hESCs [140, 141]. However, as discussed 
previously, these vectors achieve the later by integrating randomly within the 
genome. Although possessing a lesser risk of random integration, commonly used 
adenoviral vectors and AAV vectors were shown to achieve low transduction 
efficiencies in hESCs [142]. Furthermore, a study comparing gene transfer 
efficiencies between the use of viral vectors and non-viral delivery systems in hESCs 
revealed that the use of electroporation and lipofectin were the least effective 
methods at < 3% [143]. Baculoviral vectors on the other hand comprise of a wide 
mammalian cell tropism and are capable of transducing up to 80% of hESCs with no 
observable cytotoxicity [61, 88, 144]. Furthermore, vectors derived from AcMNPV 
although capable of replicating in insect cells, become replication-incompetent in 
mammalian cells, thus consisting of a property which enables its easy propagation 
and making it far less harmful in clinical applications. The use of baculoviral vectors 
also presents additional advantages such as a large cloning capacity which can 
accommodate a DNA insert up to 38 kb, rapid construction of recombinant 
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baculoviruses using routine cloning methods, and easy propagation of high viral titres 
[87]. All these features will contribute towards the successful application of BV-RMCE 
in the genetic engineering of hESCs.   
 
5.3.2 Baculovirus and Immunotoxicity   
When using viral vectors for therapeutic applications, another issue which needs to 
be addressed is immunotoxicty. In a previous study, efficient transduction of the liver 
cells was achieved in patients with haemophilia B following the hepatic infusion of an 
AAV vector expressing factor IX. However, the therapeutic benefits were short lived 
as a cell-mediated response directed against AAV antigens resulted in the 
destruction of the transduced cells [145]. A similar incident was also reported in an 
individual treated for LPL deficiency [146]. The death of a patient with partial OTC 
was reported following the hepatic infusion of an adenoviral vector expressing OTC 
[147]. When used for genetic modification of human cells, baculoviral vectors, unlike 
their lentiviral counterparts, mediate transgene expression without integrating within 
the host genome. Furthermore, the viral DNA remains episomal and degrades 
quickly in transduced mammalian cells, thus suiting the purpose of temporary 
transgene expression well [148]. These features of baculoviral transduction decrease 
the probability that ex vivo use of these vectors together with the transgenes they 
express will invoke undesired immune responses following transplantation of 
genetically engineered cells. This hypothesis however needs to be tested in future 
studies. Nonetheless, the safety of the occluded Heliothis zea baculovirus has been 
evaluated with feeding tests on volunteering human subjects with clinical tests 
showing no signs of inflammation, allergy, or side effects [149]. Furthermore, humans 
do not possess any pre-existing antibodies or T-cells directed against baculovirus 
which could therefore help prevent immunotoxicity [96].  
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 5.4 BV-RMCE in Stem Cell Research  
Seventeen years following the discovery of mESCs, James Thomson isolated a 
group of cells that would change the face of modern day science [150-152]. Since 
then, these cells, referred to as human embryonic stem cells have been regarded 
highly due to their potential in regenerative medicine and for their value in 
understanding developmental biology. 
hESCs are derived from the inner cell mass of the blastocyst and can replicate 
indefinitely. They are also pluripotent as opposed to their multipotent adult stem cell 
(ASC) counterparts which enables them to be differentiated into various cell types 
that can be used in cell-based therapy. hESC-derived progenies have been used in 
the treatment of spinal cord injury, myocardial infarction and lung injury in animal 
models and with the commencement of phase I studies of hESC-derived 
oligodendrocyte progenitor cells in the treatment of patients with spinal cord injuries, 
it is only a matter of time before their application in other clinical trials [78-80]. 
 
5.4.1 Generation of Transgenic Cells for Ex Vivo Gene Therapy and 
Regenerative Medicine 
The technique developed in the current study has made it possible to repeatedly 
integrate transgenes within the AAVS1, thus presenting the opportunity for 
introducing various therapeutic genes safely into the genome of hESCs for ex vivo 
gene therapy. Furthermore, derivation of transgenic NSCs, MSCs, DCs, glial cells 
and neurons for potential transplantation revealed that the stability of the hESC 
genome had not been compromised thereby confirming the safety of our technique. 
A point to note is that when injected into animals, undifferentiated hESCs can form 
benign tumors (teratomas) that contain a variety of tissues from all three germ layers. 
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Hence, it is imperative to ensure that transgenic hESCs do not exist (contaminate) 
together with the transplantable differentiated cells. 
Although hESCs hold a great place in the field of science, ethical concerns are 
constantly being raised regarding their origin, with certain countries and states 
banning their use for research and therapeutic purposes. Hence hESCs are in limited 
supply and harder to obtain than ASCs. An increased demand for these cells could 
lead to the transplantation of cells derived from allogenic donors, which could result 
in immunotoxicity in the recipient. However, if the transplantable progenies were to 
express HLA types corresponding to Class I MHCs identical to that of the recipient an 
immunological response directed against these cells could be averted. Through BV-
RMCE we could establish a bank of hESCs expressing various HLA types which not 
only would be a solution for the shortage of cells but also for preventing any 
undesirable immunogenic responses following transplantation. 
 
5.4.2 Understanding Developmental Biology  
Apart from their use in therapeutic applications, hESCs are a pivotal tool for studying 
early development in humans. Many birth defects and childhood cancers are a result 
of abnormal cell division and differentiation. For in vitro biological studies to identify 
genetic/molecular markers and cellular events responsible for these conditions as 
well as to understand gene function in early human development and cell type 
differentiation, the master loxP-hESC line generated in this study could be used for 
long-term expression of siRNAs in a uniform chromatin landscape for functional 





5.4.3 Screening of Drugs and Toxins for Therapeutic Applications 
Prior to being tested on patients, drug and toxin screenings were previously 
performed in differentiated human cells (in vitro) and their safety was evaluated by in 
vivo delivery into animals. However, due to their prolonged culture, cells used in 
these tests undergo multiple rounds of division and hence display different 
characteristics compared to those in vivo thus making it hard to assess the true 
nature of a compound. Using a cell type- or lineage-specific promoter in our BV-
RMCE vectors, it should also be possible to integrate transgenes within the AAVS1 in 
progenies derived from the hESC line containing loxP-docking sites. Since 
integration within this locus results in persistent expression, these transgenes could 
correspond to the endogenous genes responsible for the condition being treated and 
hence the derived progenies are more likely to mimic the true in vivo response to a 
tested compound thereby offering a safer and more accurate model for drug and 
toxin screening. Furthermore, transplantation of transgenic progenies in 
immunocompromised species provides the opportunity for generating humanised 
animal models which would enable for an even more accurate assessment of the 
compound being tested. 
 
5.4.4 Generation of iPS Cells for Regenerative Medicine     
With the discovery of mouse induced pluripotent stem (mIPS) cells and later human 
iPS cells the ethical issues and cell shortages regarding hESCs have been resolved 
to a certain extent [153-155]. Somatic cells obtained from a transplant recipient can 
be reprogrammed to display stem cell-like characteristics. There are no ethical 
concerns regarding the origin of iPS cells and as they are derived from the recipients 
themselves should possess no immunogenic properties. iPS cell-derived progenies 
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have been used in the treatment of Parkinson’s disease and  sickle cell anaemia in 
animal models [156, 157].  
Somatic cells were initially reprogrammed by the introduction of a defined 
combination of transcription factors, namely Oct3/4, Sox2, Klf4, and c-Myc. As c-Myc 
is a proto-oncogene efforts were taken to generate iPS cells by the introduction of 
alternate transcription factors [155, 158]. Although successful, these approaches 
were more time consuming and less efficient in reprogramming than the initial 
approach. Furthermore, the transcription factors used in reprogramming are 
delivered into the somatic cells via retroviral or lentiviral vectors. As discussed 
previously, although possessing the ability to induce persistent gene expression, 
these vectors can activate proto-oncogenes due to their randomly integrating nature. 
The transplantation of iPS cell-derived progenies obtained from viral transduction 
could therefore lead to tumorigenesis in the recipient. With our technology we could 
safely integrate the alternate transcription factors necessary for reprogramming 
within the AAVS1 in somatic cells and generate iPS cells containing a stabilized 
genome which can then be differentiated into progenies that serve as a source of 
transplantable cells free from immune rejection. 
 
5.4.5 Generation of Transgenic iPS Cell-Derived Progenies for Ex Vivo 
Gene Therapy  
To prevent random integration, since they exist episomally, plasmids and adenoviral 
vectors have been used to deliver the necessary transcription factors but as the 
expression produced by these vectors is transient, the reprogramming efficiency is 
significantly diminished [159, 160]. The use of a piggybac transposition system 
however has enabled for persistent gene expression without random integration 
[161]. Apart from the introduction of DNA, successful reprogramming has also been 
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achieved by using recombinant proteins, synthetic modified mRNAs as well as 
microRNAs [162-165]. Furthermore, enhanced reprogramming efficiencies have 
been achieved with the use of small-molecule compounds [166]. Therefore, apart 
from generating iPS cells, BV-RMCE could also be applied in cells reprogrammed by 
non-viral delivery systems to integrate various therapeutic genes within the AAVS1. 
The progenies derived from these transgenic iPS cells could be used in ex vivo gene 
therapy. A point to note is that doubts have been raised regarding the pluripotency of 
iPS cells, and whether they too can be differentiated into virtually any cell type. This 
concern was attributed to a study which revealed that mIPS cells retained epigenetic 
memory from their origin and were thus inclined to differentiate along the lineage 
from which they were derived [167]. This property could influence the directed 
differentiation required for therapeutic applications. 
 
5.4.6 Adeno-Associated Virus Infection of Transgenic Cells  
With the AAVS1-modified hESCs as a starting material for generating transgenic 
hESCs, the time spent on laborious screening of genetically modified hESC clones 
will be significantly reduced. As discussed previously, the AAV2 is a common non-
pathogenic human virus that preferentially integrates its genome within the AAVS1. 
Hence, there may be concerns as to what may happen if this virus were to infect the 
cells genetically modified through BV-RMCE. A recent study using an unbiased 
genome-wide analysis of wild-type AAV2 integration events revealed that the 
integration sites are scattered throughout the human genome, with only 10% of the 
total integration hotspots being located within the AAVS1[168]. Targeted integration 
of this locus by wild-type AAV2 is therefore not as specific as previously assumed. 
Furthermore, since genetic modification by homologous recombination and BV-
RMCE will disrupt the AAVS1 in one out of the two homologous chromosomes 19 (as 
revealed by our Southern blot analysis), we speculate that this locus will have 
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significantly reduced functionality as an integration site for AAV2. This would further 
diminish the chances of deleterious interactions between wild-type AAV2 and the 
integrated transgene. 
Through this discussion it would seem that both hESCs and iPS cells have their own 
unique advantages and disadvantages and hence the current task at hand is to 
weigh the pros and cons associated with these cell types and assert which of the two 
is more (i) efficient for therapeutic applications and (ii) safer following their 
transplantation. With the potential for understanding early human development 
together with its application in ex vivo gene therapy and iPS cell generation, BV-
















Previous studies have revealed that the AAVS1 in hESCs could be targeted either by 
utilising AAV2 technology, ZFNs or TALENs [45, 66, 71]. To circumvent some 
potential limitations associated with these methods, we have in the current study 
developed a novel approach for such genetic modification by utilising a two-step 
process combining homologous recombination with BV-RMCE. Although time-
consuming, the generated master loxP-hESC line provides rich opportunities for 
readily introducing transgenes into the AAVS1 through efficient RMCE. The targeting 
efficiency achieved in the master hESC line by our BV-RMCE technique was almost 
100%, which is significantly much higher than what has been achieved when utilising 
AAV2 technology. Since our method does not use an enzyme to induce DNA double-
strand breaks (DSB) it could be less complicated in being translated into clinical 
applications. Furthermore, by integrating the HSVtk suicide gene within the AAVS1 
we obtained a genetically modified functional NSC population possessing tumor 
migratory properties and the ability to induce gap-junction mediated bystander killing 
effects in glioma cells thereby demonstrating the clinical potential of the genetic 
modification approach developed in this study.  
The preliminary results obtained from the BV-ZFN study demonstrates the system’s 
ability to mediate homologous recombination and induce persistent transgene 
expression in the absence of drug selection and in doing so provides an alternate 
and more effective approach than conventional homologous recombination. BV-ZFN 
technology also eliminates the need for biphasic selection as only one round of drug 
selection will be required during cassette exchange. With a floxed reporter gene 
cassette, (as opposed to a floxed neomycin cassette) single-cell sorting can be 
achieved through FACS, thus providing the opportunity for obtaining pure genetically 
modified master loxP-cell lines. Through BV-ZFN technology the introduction of 
heterospecific loxP sites into the AAVS1 of any cell type will be less arduous and 
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timesaving. Currently, via this approach we are attempting to generate a loxP-iPS 
cell line from which transgenic progenies expressing various therapeutic genes can 
be derived through BV-RMCE.  
We also have plans to develop a baculovirus-TALEN (BV-TALEN) hybrid system in 
the near future. The use of TALENs to genetically modify human cells is a relatively 
new approach and there is much to learn regarding their safety. However, their high 
degree of sequence specificity may reduce or perhaps even completely eliminate the 
risk of off-target DSB. Furthermore, despite their size, the efficient delivery of these 
nucleases can be made possible due to the large cloning capacity of baculoviral 
vectors. A comparison between BV-ZFN and BV-TALEN technologies will provide 
valuable insight with regard to their targeting efficiencies at the AAVS1 as well as 
their safety.  
In conclusion, the key contributions of the current study include confirming the 
feasibility of homologous recombination at the AAVS1, demonstrating the high 
efficiency of BV-RMCE, and developing a two-step process combining homologous 
recombination with BV-RMCE for site-specific genetic modifications of hESCs. The 
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List of primers used in current study 






















Homologous recombination (EGFP) detection (BV-ZFN technology) 
Forward: GCGACGTAAACGGCCACAAGTTCAG 
Reverse: GGAACGGGGCTCAGTCTG  
 



















Probe for site-specific integration (EGFP) detection 
Forward: TTACTTGTACAGCTCGTCCATGCCG 
Reverse: TACGGCAAGCTGACCCTGAAGTTCA 
 
 
Actin detection 
Forward: CAGCAAGCAGGAGTATGACG 
Reverse: AGTGGGGTGGCTTTTAGGAT 
 
AFP detection 
Forward: AGAACCTGTCACAAGCTGTG 
Reverse: GACAGCAAGCTGAGGATGTC 
 
Brachyury detection 
Forward: CAACCACCGCTGGAAGTAC 
Reverse: CCGCTATGAACTGGGTCTC 
 
Nanog detection 
Forward: GCGCGGTCTTGGCTCACTGC 
Reverse: GCCTCCCAATCCCAAACAATACGA 
 
Nestin detection 
Forward: GAAACAGCCATAGAGGGCAAA 
Reverse: TGGTTTTCCAGAGTCTTCAGTGA 
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NeuroD detection 
Forward: GAGACTATCACTGCTCAGGA 
Reverse: GATAAGCCCTTGCAAAGCGT 
 
Oct-3/4 detection 
Forward: CTTGCTGCAGAAGTGGGTGGAGGAA 
Reverse: CTGCAGTGTGGGTTTCGGGCA 
 
Pax6 detection 
Forward: AACAGACACAGCCCTCACAAACA 
Reverse: CGGGAACTTGAACTGGAACTGAC 
 
SOX1 detection 
Forward: CAATGCGGGGAGGAGAAGTC 
Reverse: CTCCTCTGGACCAAACTGTG 
 
SOX2 detection 
Forward: TGGACAGTTACGCGCACAT 
Reverse: CGAGTAGGACATGCTGTAGGT 
 
EGFP detection 
Forward: AGCCGCTACCCCGACCACAT 
Reverse: CGTCGCCGATGGGGGTGTTC 
 
HSVtk detection 
Forward: CACGTTATACAGGTCGCCGT 
Reverse: TACTTGCCAATACGGTGCGG 
 
 
 
 
 
